

Trends in organic micropollutants removal in secondary treatment of sewage

T. Alvarino, J. Lema, F. Omil & S. Suárez

Author's Accepted Manuscript (AAM)

This is a post-peer-review, pre-copyedit version of an article published in *Reviews in Environmental Science and Bio/Technology* volume. The final authenticated version is available online at: <https://doi.org/10.1007/s11157-018-9472-3>

How to cite:

Alvarino, T., Lema, J., Omil, F. et al. Trends in organic micropollutants removal in secondary treatment of sewage. *Rev Environ Sci Biotechnol* 17, 447–469 (2018).
<https://doi.org/10.1007/s11157-018-9472-3>

Copyright information:

© Springer Nature B.V. 2018.

1 Trends in organic micropollutants removal in secondary treatment of sewage

2 T. Alvarino^{1*}, J. Lema¹, F. Omil¹, S. Suarez¹

3 ¹Department of Chemical Engineering, Institute of Technology, School of Engineering,
4 University of Santiago de Compostela, E-15782 Santiago de Compostela, Spain

5 *Corresponding author. ter.alva@gmail.com; Tel.: +34-881816739; ID ORCID: 0000-
6 0001-8348-8387

9 Acknowledgments

10 This research was supported by the Ministerio de Economía y Competitividad (AEI)
11 through the Project COMETT (CTQ2016-80847-R). The authors belong to the Galician
12 Competitive Research Group GRC2013-032 and to the CRETUS Strategic Partnership
13 (AGRUP2015/02). All these programs and project are co-funded by FEDER (UE).

15 Abstract

16 Organic micropollutants (OMPs) comprise a wide group of substances highly consumed
17 in modern societies. There has been a growing social and scientific interest on OMPs in
18 wastewaters in the 21st century. This research paper has identified the evolution of the
19 research trends in the period 2001-2017 on OMPs fate during secondary wastewater
20 treatment. These trends have moved from a global perspective on the occurrence of OMPs
21 in wastewaters to more specific research focussed on understanding their behaviour
22 during advanced treatment processes. Based on a bibliometric analysis carried out using
23 one of the leading scientific databases, pharmaceuticals have been identified as the main
24 group of OMPs. An increasing number of publications have been released on the fate of
25 pharmaceuticals in wastewater with a growing number of countries involved: from 38
26 publications belonging to 14 countries in first 5-year period analysed (2001-2005) up to
27 138 from 42 countries only in the last two years (2016-2017). The main operational
28 conditions in wastewater treatment plants influencing the removal of OMPs, as well as
29 the mechanisms involved depending on the physico-chemical characteristics of the
30 substances are reviewed. The paper also considers the role of microbial populations, as
31 well as technological and operational features in OMPs abatement. Finally, a specific
32 section is dedicated to the metabolic and cometabolic biotransformations of some OMPs
33 taking place under heterotrophic, nitrifying and anaerobic conditions, a more novel
34 research trend explored more recently.

35 *Keywords:* advanced treatments, biotransformation, cometabolism, operational
36 conditions, organic micropollutants, removal mechanisms

37

39 **1. Introduction**

40 The abatement of “emerging pollutants” is becoming a specific target in the conception
41 of modern wastewater treatment schemes. In most cases the term used should be
42 “pollutants of emerging concern”, since what is really new is the information recently
43 obtained with the modern powerful analytical techniques which allow measuring
44 concentrations of almost every compound consumed by our society at extremely low
45 concentrations. Most of these pollutants are characterized by their occurrence at trace
46 level, being consequently also referred to as micropollutants. Most of them have an
47 organic nature, consequently called organic micropollutants (OMPs).

48 OMPs comprise a wide group of substances largely consumed in modern societies (Omil
49 et al., 2010), including pharmaceuticals, endocrine disruptors (EDCs), personal care
50 products (PCPs), biocides, brominated flame retardants (BFRs), pesticides and linear
51 alkylbenzene sulphonates (LAS). In general, the production of these substances has been
52 increasing during the last years even though the population trend in many developed
53 countries is hardly stable or declining, which constitutes an indication of the progressive
54 higher consumption per capita of pharmaceuticals, hormones, other therapeutic
55 substances, cosmetics, etc. The aging of society plays a key role in such trend, but also
56 other changes in social habits are relevant, as for example the access to contraception,
57 which supposes an increasing consumption of the hormone 17 α -ethinylestradiol (EE2,
58 the active ingredient of the contraceptive pill). The extensive use of antibiotics, new
59 antiviral drugs or disinfectants is another example of the wide distribution of these
60 substances in our society (Van der Aa et al., 2011).

61 Pharmacokinetics is the study of the time course of drug absorption, distribution,
62 metabolism, and excretion from the body (usually into the water cycle). It is a key issue
63 to estimate the concentration of pharmaceuticals and endocrine disruptors in wastewaters,
64 together with their consumption and disposal patterns (Ortiz de Garcia et al., 2013; Besse
65 et al., 2008; Kolpin et al., 2004). In fact, compounds with a low excretion rate, such as
66 ibuprofen (IBP), diclofenac (DCF) or sulfamethoxazole (SMX), are usually present at
67 noticeable concentrations in wastewaters due to their massive use (Kolpin et al., 2004).
68 Other important factors to be considered are the diurnal occurrence patterns, which are
69 correlated with the daily drug administration (Plósz et al., 2010) and with the climate
70 conditions. In this sense, increases in the concentration of pharmaceuticals in wastewater
71 were observed under dry weather conditions in combined sewer systems (Kasprzyk-
72 Hordern et al., 2009). A seasonal influence on the concentrations of several
73 pharmaceuticals, such as IBP and ketoprofen (KET) has been reported (Santos et al.,
74 2009).

75 In wastewater treatment plants (WWTP), high variations in the inlet OMP concentrations
76 can be found. This occurs in one installation along a period of time but especially when
77 comparing data from different plants (Miège et al., 2009; Mussolf et al., 2009; Spongberg

78 and Witter, 2008; Ellis, 2006; Carballa et al., 2004). The usual influent concentrations of
79 OMPs in WWTPs are in the range of $\mu\text{g L}^{-1}$ and ng L^{-1} . For example, some musk
80 fragrances, such as galaxolide (HHCB), tonalide (AHTN) or celestolide (ADBI), widely
81 used in the formulation of cosmetic products, have been found at concentrations ranging
82 between 0.9-16.6 $\mu\text{g L}^{-1}$ (Clara et al., 2011; Carballa et al., 2004). The anti-inflammatories
83 IBP, naproxen (NPX) or DCF were found in a wider range, going from 12 ng L^{-1} to 84 μg
84 L^{-1} (Gómez et al., 2007; Kim et al., 2007; Nakada et al., 2006; Vieno et al., 2005).
85 Hormones are present in sewage at the lowest concentration ranges, usually below 50 ng
86 L^{-1} (Belhaj et al., 2008; Carballa et al., 2004), as expected from the low medication drug
87 doses prescribed.

88 1.1 Concerns of the society related to OMP emissions

89 The growing social interest in this topic is evidenced by the increasing number of news
90 all around the world which can be found in different mass media. Since the concentrations
91 of OMPs in water (wastewaters, surface waters, groundwater) are extremely low,
92 especially when compared to conventional macropollutants, the reasons for such concern
93 are not related to their chemical impact, but to other potential problems (toxicity,
94 bioaccumulation and estrogenicity caused to the micro and macroorganisms exposed to
95 these emissions). Adverse effects on fishes exposed to the anti-inflammatory diclofenac
96 at 0.5-1 $\mu\text{g L}^{-1}$ have been reported by Hoeger et al. (2005) and Triebkorn et al. (2004).
97 Eguchi et al. (2004) studied the toxicity of different antibiotics such as erythromycin
98 (ERY), oxytetracycline and tylosin on the green algae *Selenastrum capricornutum*. The
99 endocrine disrupting effect of the estrogens 17 β -estradiol (E2) and the synthetic EE2 was
100 observed in different organisms, including fishes (Parrott and Blunt, 2005; Hirai et al.,
101 2006; Orlando et al., 2007).

102 As a consequence, the European Union decided in 2015 to include 7 OMPs in the “Watch
103 List” of the Water Framework Directive (WFD) to discuss the future limits of discharge
104 of these substances, namely 3 hormones (estrone, E1, E2 and EE2) and 4 pharmaceuticals
105 (diclofenac and the macrolide antibiotics azithromycin, clarithromycin and ERY) due to
106 their estrogenic, toxic or antibacterial resistance potential (Table 1). The aim of this
107 legislative measure is to monitor and gather information regarding the potential risks
108 related to the exposure to those OMPs in the aquatic environment.

109 *Table 1. European Union legislation in terms of organic micropollutants*

110 The Swiss Federal Office for the Environment (FOEN) can be highlighted as pioneer in
111 developing a legal framework for OMP emissions in wastewater effluents. A new Water
112 Protection Ordinance has been applied since 2015 in order to reduce the levels of
113 micropollutants in their water bodies. The Swiss legislation is targeting the protection of
114 sensitive waters and drinking water sources by limiting the OMP content in treated
115 wastewater below 20% of the concentration present in the raw wastewater. The selection
116 of the target OMPs has been carried out based in extensive research programmes carried

117 out along the Swiss territory for a number of years (www.bafu.admin.ch). As a general
118 rule, the substances which appeared most frequently and were not removed during
119 biological treatment were selected. Each canton in Switzerland has to select 6 of a list of
120 12 substances for which WWTPs have to achieve removal efficiencies above 80% after
121 upgrading to advanced treatment based on ozone or activated carbon. This list comprises
122 the following compounds: amisulpride, carbamazepine, citalopram, clarithromycin,
123 diclofenac, hydrochlorothiazide, metoprolol, venlafaxine, benzotriazole, candesartan,
124 irbesartan and mecoprop.

125 **1.2 Research trends compared to state of the art**

126 In order to analyse the evolution of the scientific community focus concerning OMPs in
127 wastewater, a bibliometric study has been carried out following the strategy: Source
128 *Scopus (Title-abstract-keywords)*; Search *pharmaceuticals* and *wastewater*; period *from*
129 *2001 to 2017*. In general, the studies related to pharmaceuticals during wastewater
130 treatment have been increasing exponentially in the last decades, moving from a limited
131 perspective mainly oriented to the occurrence to a research with an increased level of
132 detail and complexity, as will be demonstrated in the following paragraphs.

133 According to the scientific background, firstly the analytical methods were developed and
134 optimized for the measurement of OMPs concentrations in different matrixes (from
135 milliQ water to the complex mixed liquors existing in WWTPs) with the aim of assessing
136 their occurrence in the different compartments and streams of WWTPs (Ternes et al.,
137 2001; Buser et al., 1998; Hirsch et al., 1998; Huppert et al., 1998). These first studies
138 reported a high variability in the removal efficiencies of OMPs in wastewater treatment
139 using similar treatment schemes (Table 2), which was attributed to the differences in the
140 environmental and operational conditions applied (hydraulic retention time, HRT; solid
141 retention time, SRT, etc.). Consequently, the influence of those conditions on OMP
142 removal was the main objective of many studies (Maeng et al., 2013; Gerrity et al., 2011).
143 Most of efforts carried out to elucidate the behaviour of OMPs along WWTPs have
144 focussed on the determination of the overall removal efficiencies achieved by different
145 technologies (activated sludge, membrane reactors, posttreatments, etc.) working under
146 different operational conditions (Clara et al., 2005a; Reif et al., 2008) and only in few
147 cases the removal mechanisms in each specific case were the subject of the research
148 (Carballa et al., 2007; 2004; Alvarino 2014). Attention was especially paid to the sorption
149 and/or biotransformation of OMPs. In this sense, Ternes et al. (2004) reported a rapid
150 method to measure the solid-water distribution coefficient to determine sorption of
151 pharmaceuticals onto sludge, whereas Joss et al. (2005) studied sorption and
152 biotransformation of different pharmaceuticals and musk fragrances taking place in
153 biological reactors of WWTPs.

154 **Table 2.** Overall ranges for removal efficiencies reported for selected OMPs in wastewater
155 treatment (Behera et al., 2011; Lin et al., 2010; Gómez et al., 2007; Kupper et al., 2006; Nakada et al.,
156 2006; Bester, 2005; de Mes et al., 2005; Carballa et al., 2004; Baronti et al., 2000; Stumpf et al., 1999;
157 Ternes et al., 1998)

158 Along the last years, the number of works following this approach has been increasing,
159 with the aim of applying this knowledge to the design and development of innovative
160 wastewater treatment technologies able to remove OMPs more efficiently. New
161 technological approaches include hybrid reactors, the use of membranes, supports and/or
162 adsorbents (Escolà-Casas et al., 2015; Falås et al., 2013), post-treatment with activated
163 carbon or ozone (Kovalova et al., 2013; Margot et al., 2013), etc. These new treatment
164 strategies are conceived for including modifications in the existing plants (not only related
165 with their physical configuration but also their way of operation) and also for constructing
166 new installations. In both scenarios, the formulation of a conceptual design to maximise
167 OMPs removal requires a detailed knowledge about key mechanisms involved in their
168 transformation, being the analysis of the processes at macroscopic level not sufficient.
169 This was the starting point for more specific studies such as those addressing primary and
170 secondary metabolism, metabolic pathways and even enzymatic activities.

171 The aim of the present review is to obtain a clear picture of the main issues involved in
172 this challenging topic, focussing on the evolution observed along the first 17 years of this
173 century, based on an extensive bibliometric study. This period matches with the time
174 passed from the adoption of the WFD (October 2000) up to the final inclusion of the first
175 group of pharmaceutical OMPs in the “Watch List” (2015). Besides, the last two years
176 2016-2017 can be an indicative of the impact of such decision. The article is structured
177 according to the time evolution of the main topics identified in Fig. 1: i) occurrence and
178 fate; ii) influence of operational conditions applied in WWTPs; iii) identification of
179 removal mechanisms; iv) technological concepts addressing OMP removal and v)
180 metabolism/cometabolism.

181 *Fig. 1 Evolution of research trends dealing with OMPs in WWTPs*

182

183 **2. Occurrence and fate**

184 Fig 2A shows the number of publications along the period 2001-2017 for different groups
185 of OMPs. A clear growing trend can be observed for all categories. In the case of
186 pharmaceuticals, PCPs and BFRs, around 70% of publications were released in the last 7
187 years. Somewhat lower values (50-60%) were found for the rest of compounds. In the
188 case of pesticides and biocides, the relative number of publications in the period 2001-
189 2005 was already significant, indicating that the concern on those persistent organic
190 pollutants started earlier than those related to pharmaceuticals and personal care products.
191 The number of works containing the terms “wastewater” and the specific group of OMP
192 were: 4663 with “pharmaceutical”, 1002 with “PCP”, 1170 with “EDC”, 1183 with
193 “pesticide”, 320 with “biocide”, 172 with “LAS” and finally 92 “BFR” (Figure 2A). Thus,
194 among these 7 categories, half of the scientific interest was focussed on pharmaceuticals
195 along the entire 17 years considered.

196 *Fig. 2 Scientific papers published along 2001-2017: A) types of OMPs in wastewater;*
197 *B) selected pharmaceuticals and estrogens in wastewaters; C) fate of pharmaceuticals in*
198 *wastewaters*
199 *(Source: Scopus; General Search: GS; Specific Search: SS. Full spelling of terms was used in*
200 *the search).*

201 Among the wide number of pharmaceuticals and EDCs reported, it is interesting to note
202 that some specific substances are present in a growing number of articles, such as three
203 specific pharmaceuticals (DCF, ERY and carbamazepine, CBZ) and three hormones (E1,
204 E2, EE2), as shown in Fig. 2B. One of the factors explaining their consideration as
205 representative OMPs is their inclusion in the European and/or Swiss legislation.
206 According to the number of publications, those related to DCF, E2 and CBZ in wastewater
207 represent the double compared to the other 3 compounds (around 1000 vs. 500,
208 respectively). If their time evolution is analysed, DCF, ERY and CBZ show a stepwise
209 increasing trend especially highlighted since 2011. In fact, around 70% of their respective
210 publications were released in the last 7 years. In the case of ERY this trend could be
211 related to the current concern about antimicrobial resistance derived from the discharge
212 of antibiotics into the environment. Within the hormones, E2 received more attention
213 compared to EE2 and E1, although EE2 has shown to be a more potent endocrine
214 disruptor than the natural hormones with in vivo juvenile rainbow trout screening assays
215 (Thorpe et al., 2003). For these EDCs, the interest in publication increased especially in
216 period 2006-2010, while the figures related to the period 2011-2017 reveal a certain
217 stabilization trend.

218 If the bibliometric search is refined from pharmaceuticals in “wastewater” to “fate of
219 pharmaceuticals in wastewater”, which is related to a more technological approach, the
220 number of studies decreases in one order of magnitude, as illustrated by Fig. 2C, with 578
221 works along the 17 years analysed. Although publications with a global perspective on
222 the fate of pharmaceuticals in wastewater treatment are clearly the most abundant, other
223 on more specific topics, such as the identification of the main removal mechanisms and
224 the development of technologies targeting pharmaceutical removal have evidenced a
225 growing trend (Fig. 2C). This is especially clear along the last two years, when the
226 publications related to “fate” already achieved 52% of those corresponding to 2011-2015,
227 and in the case of “removal mechanisms” an outstanding value of 111% was achieved.
228 On the other hand, studies about the role of primary/secondary metabolism on
229 pharmaceuticals biotransformation are very scarce, with only 6 articles found since 2006.
230 Publications tackling the study of pharmaceutical removal mechanisms suppose a 9% of
231 the total publications on the fate of pharmaceuticals in WWTPs, whereas only 1% deals
232 with the primary/secondary metabolism responsible for pharmaceutical
233 biotransformation.

234 The geographical involvement of the scientific community in the study of the fate of
235 pharmaceuticals in wastewater has been changing over time. In Fig. 3 the total number of
236 publications per country origin (PCO) for each period is shown. It represents the number

237 of publications in which research groups from a given country were involved. The first
238 works were concentrated in only 14 countries, with an outstanding productivity in the
239 United States, Germany and Switzerland (Fig. 3A). In fact, the US has been leading the
240 number of publications in all periods analysed. The number of countries involved in this
241 research has been continuously increasing, achieving a total number of 42 in the last two
242 years (2016-2017). China started to publish on this topic later in 2006, reaching the
243 second position from 2011 onwards. A similar trend can be observed for Canada. Spain
244 moved from a modest position in 2001-2005 to the top-4 in the following 12 years. Since
245 the beginning, UK, France and Australia maintained a quite stable position in the ranking,
246 while other countries as for example Switzerland left the topic in the last 7 years. Most
247 probably, this was because the OMP presence in wastewaters has been incorporated into
248 Swiss regulations moving the challenge to full-scale implementation. Besides, it is worth
249 to note the increasing number of developing countries all around the world that have
250 started focussing their attention on this issue in the last two years. India, Taiwan, Brazil
251 and Pakistan are examples of this evolution.

252 In order to identify the main research trends in the different countries, Fig. 4 shows the
253 previous search (Fig. 2C) refined with three selected research fields: removal mechanism,
254 technology and co-metabolism. In the first case, Fig. 4A shows that groups from 23
255 countries have been involved in the assessment of removal mechanisms, being observed
256 that 50% of the pie chart belongs to four countries: United States, China, Germany and
257 Spain. In the case of technologies, Switzerland, Canada and Great Britain are also present
258 in the first positions from a total of 29 countries involved (Fig. 4B). Few articles address
259 the role of the cometabolic biotransformations taking place during the abatement of
260 pharmaceuticals, belonging to research groups from the United States, followed by
261 France, China, Spain and, more recently, Denmark (Fig. 4C).

262 The number of collaborations between research groups from different countries working
263 on the fate of pharmaceuticals in wastewaters can be analysed from the ratio between the
264 sum of publications per country origin (SPCO) in Fig. 3 and the sum of publications (SP)
265 corresponding to a certain period (Fig. 2). The ratio SPCO/SP was of 1.21, 1.34, 1.33 and
266 1.41 going from the first (2001-2005) to the fourth (2016-2017) period considered,
267 respectively. These numbers evidence the increasing trend in the collaborations between
268 research groups from different countries on that topic.

269

270 *Fig. 3 Publications per country origin focussed on the fate of pharmaceuticals in wastewater in*
271 *the period 2001-2017 classified by country (source: Scopus; GS: pharmaceutical, wastewater,*
272 *fate; SS: period; country codes according to ISO 3166)*

273

274 *Fig. 4 Publications per country origin dealing with the different research fields focussed on fate*
275 *of pharmaceuticals in wastewater in the period 2001-2017 classified by country*

276 (source: Scopus; GS: pharmaceutical, wastewater, fate; SS: research field;
277 country codes according to ISO 3166)

278

279 **3. Influence of operational conditions**

280 There is not a unique classification of OMPs in function of their removal in WWTP due
281 to the broad ranges of removal efficiencies reported for most of these compounds
282 (Table 2). This different behaviour could be partially explained in terms of the different
283 environmental and operational conditions applied in each case, such as HRT, SRT and
284 redox conditions (Table 3). For instance, IBP is considered one of the most readily
285 biodegradable OMPs in conventional biological treatments (Clara et al., 2005a; Carballa
286 et al., 2004). However, IBP is a recalcitrant compound under anaerobic conditions
287 (Alvarino et al., 2014).

288 *Table 3. Influence of SRT, HRT and temperature in the removal of OMPs (Fernandez-Fontaina et*
289 *al., 2012; Reif et al., 2011; Suárez et al., 2010; Clara et al., 2005b; Tauxe-Wuersch et al., 2005)*

290

291 **3.1 Hydraulic and sludge retention time**

292 Maurer et al. (2007) observed that the removal efficiencies of some betablockers strongly
293 correlated with the HRT. Clara et al. (2005a) reported a high dependence of the behaviour
294 of the anti-inflammatory DCF, with removal efficiencies around 70% at long HRTs (13
295 d) which became negligible when a lower HRT was applied (1.2 d). Fernandez-Fontaina
296 et al. (2012) reported an increase in the removal of ROX and FLX at higher HRTs,
297 whereas no influence of the HRT was observed for IBP and NPX. These differences can
298 be related to kinetic limitations, which are especially relevant in the case of the
299 compounds with medium biodegradability.

300 The operation at high SRT allows the increase of the microbial diversity due to the
301 development of slowly growing bacteria, as well as higher biomass concentrations and
302 better acclimation to disturbances and toxic substances (Clara et al., 2005b). De la Torre
303 et al. (2015) operated an IFAS-MBR (a membrane bioreactor which combines suspended
304 and fixed biomass) at different SRTs (10 and 20 d). Higher removal efficiencies of
305 pharmaceuticals were observed when operating at an SRT of 20 d. Surprisingly, a removal
306 efficiency above 80% was reported for carbamazepine in the IFAS-MBR operated at an
307 SRT of 20 d (De la Torre et al., 2015), which was related to the operation at low F/M
308 ratios which induced the microorganisms to biotransform the recalcitrant compounds
309 (Verlicchi et al., 2012). Suárez et al. (2012) reported a significant influence of the SRT on
310 the removal of lipophilic compounds, such as estrogens or musk fragrances. For instance,
311 EE2 removal increased 11% when the SRT was maintained above 20 d. For these
312 compounds, a stronger influence of the SRT compared to the HRT was reported, based
313 on the assumption that compounds with a low biological kinetic constant can be

314 biologically transformed at high SRTs if they are mainly sorbed onto the sludge. Reif et
315 al. (2011) compared the removal of OMPs in a MBR operated with a SRT of 6 and 20 d
316 and observed a reduction in the discharge of acidic drugs and musk fragrances in the final
317 effluent at the higher SRT. In fact, Clara et al. (2005b) identified that SRT > 10 d increased
318 removals for several OMPs, such as hormones and ibuprofen. The enhancement in the
319 removal of certain OMPs when the SRT is increased has been related to the presence of
320 slowly growing nitrifiers (Miège et al., 2009; Göbel et al., 2007; Clara et al., 2005b), as
321 occurs with ibuprofen, estrone or estradiol, whose removal has been correlated with the
322 nitrification activity (Alvarino et al., 2016a).

323

324 **3.2 Redox conditions**

325 Redox conditions strongly influence the degree and route of OMP biotransformation. The
326 OMP behaviour is mainly related to the chemical structure of the compound and the
327 metabolic pathways promoted under each environment (Fig. 5 and 6). In general, OMPs
328 are removed to a higher extent under aerobic conditions (Alvarino et al., 2018). For
329 instance, a recalcitrant behaviour was reported by McAvoy et al. (2002) in the case of
330 triclosan under anaerobic conditions, while it was a readily removed in aerobic processes.
331 However, some pharmaceuticals, like SMX or NPX, were easily removed at negative
332 redox conditions, with removal efficiencies above 99% for SMX during the anaerobic
333 digestion of sludge (Carballa et al., 2007a). Comparing the aerobic and anoxic removal
334 of OMPs, it was reported that most of the compounds were efficiently removed under
335 aerobic conditions, whereas three compounds (ROX, CLA, and clindamycin (CLI)) were
336 removed only under anoxic conditions (Burke et al., 2014). In general, the operation of
337 biological reactors at different redox conditions results in an increased microbial diversity
338 and a broader enzyme spectrum which enhances OMPs biotransformation (Suárez et al.,
339 2012).

340 *Fig. 5. Biotransformable and recalcitrant moieties under anaerobic conditions*

341 *Fig. 6. Biotransformable and recalcitrant groups under aerobic conditions*

342

343 *3.2.1 Anaerobic conditions*

344 The presence of electron-withdrawing groups enhances the removal of OMPs by
345 reductive biotransformation reactions (Banzhaf et al., 2012; Field, 2002), whereas the
346 cyclic or heterocyclic groups or the halogens in the chemical structure difficult the
347 removal under anaerobic conditions (Fig. 5, Dutta et al., 2014; Monsalvo et al., 2014;
348 Musson et al., 2010; Adrian et al., 1994), as in the case of progesterone, DCF, CBZ or
349 DZP. The substituted heterocycles are susceptible to be degraded under anaerobic
350 conditions (Adrian et al., 1994). This was the case in the metabolic route proposed by

351 Alvarino et al. (2016b) for SMX removal in a pure anaerobic culture being the attack site
352 in the substituted heterocycle 3-amino-5-methyl-isoxazole ring.

353 Under negative redox conditions, OMPs removal can occur by hydrogenation or
354 hydroxylation reactions. The hydroxylation of the carbons present in the aromatic ring
355 promotes the ring cleavage under anaerobic conditions. However, the hydroxylation can
356 be interfered by some ring substitutions, as in the case of acetaminophen. Its low removal
357 might be associated with the branched chain substitution in the aromatic ring (Musson et
358 al., 2010). Carboxylic and hydroxyl functional groups promote the hydroxylation
359 (Musson et al., 2010). For instance, metoprolol (MTP) is an OMP with a medium-high
360 removal because its structure contains a hydroxyl moiety, in spite of the presence of an
361 amine group that is recalcitrant under anaerobic conditions (Musson et al., 2010).
362 Nonylphenol and the short-chain nonylphenol ethoxylates are the intermediate products
363 of the anaerobic removal of the surfactant nonylphenol ethoxylates due to the sequential
364 removal of ethoxyl groups (Lu et al., 2008, 2007). Falås et al. (2016) observed the
365 demethylation and deionation of organic micropollutants with a recalcitrant behavior
366 under aerobic conditions, such as diatrizoate or venlafaxine, in an anaerobic posttreatment.

367

368 3.2.2 Aerobic conditions

369 Under aerobic conditions, Boethling et al. (1994) showed that the presence of heterocyclic
370 N-containing aromatic rings hampers biodegradation (Fig. 6), which explains the stability
371 of CBZ that contains three fused aromatic rings (Fernandez-Fontaina et al., 2016). The
372 presence of chlorine atoms in the OMP structure generates an electron deficiency, thus
373 the molecule is less susceptible to oxidative catabolism (Knackmuss, 1996; Keener and
374 Arp, 1993). The micropollutants with electron donating functional groups, such as amines
375 or hydroxyl groups, are more prone to be biotransformed by an electrophilic attack by
376 oxygenase enzymes (Tadkaew et al., 2011). For instance, Müller et al. (2013) studied the
377 biotransformation of SMX under aerobic conditions and 3-amino-5-methyl-isoxazole
378 was the main stable metabolite detected, being the attack site in the amine. Jewell et al.
379 (2016) observed the removal of TMP by demethylation to form the intermediate
380 metabolite 4-desmethyl-TMP under aerobic conditions. This metabolite was not stable
381 and quickly transformed to 2,4-diaminopyrimidine-5-carboxylic acid by hydroxylation
382 and oxidation. Other authors showed another biotransformation pathway for TMP by
383 ether cleavage (Quintana et al., 2005).

384 A wide range of polycyclic aromatic hydrocarbons, aryl ethers and aromatic ethers, such
385 as naphthalene (NAP), diphenyl ether (DE) or anisole can be cometabolically degraded
386 through O-dealkylation or hydroxylation by the ammonia monooxygenase (AMO)
387 enzyme, produced by ammonium oxidizing bacteria (Chang et al., 1997), as well as the
388 straight-chain hydrocarbons through hydroxylation (Hyman et al., 1988). Tadkaew et al.
389 (2011) showed a high removal of micropollutants with an aromatic-aliphatic ether, such
390 as gemfibrozil (98%) and verapamil (87%), that can be biotransformed by ether cleavage.

391 Dorival-Garcia et al. (2013) observed a medium removal of the quinolone antibiotics (14-
392 40%) under aerobic conditions, while the biodegradation was negligible under anoxic
393 environments. This difference can be related to the higher oxidation potential of the
394 oxygen, compared to the nitrate (Sigg, 2000), since redox reactions occur in the order of
395 the thermodynamic conditions, being oxygen the lowest unoccupied electron level
396 (Stumm and Morgan, 1996). Due to that, the hydrolysis of primary and secondary amides
397 can occur under both redox conditions, while the oxidation of tertiary amides is viable
398 only under aerobic conditions (Helbling et al., 2010).

399

400 **4. Identification of the OMP main removal mechanisms**

401 Once the occurrence and fate of the OMPs are accurately determined in WWTPs, the next
402 step consists in the understanding of the behaviour of these substances during biological
403 treatment. Taking into account the three phases in which the OMPs can be present in a
404 biological reactor (solid, liquid and gas streams), three main removal mechanisms can be
405 distinguished: biotransformation, sorption, and volatilization (Pomiès et al., 2013; Joss et
406 al., 2006). Volatilization and sorption consist in the transfer of OMPs between two
407 compartments based on equilibrium mechanisms (liquid-gas, and liquid-solid,
408 respectively), whereas biotransformation is the degradation of the parent OMP in the
409 mixed liquor (Pomiès et al., 2013). In WWTPs, the fate and behaviour of OMPs strongly
410 depend on the physicochemical properties of the compound (Boethling et al., 2007) and
411 the type of treatment processes applied (physicochemical or biological).

412 Volatilisation depends on the physicochemical properties of the OMPs, such as the Henry
413 law constant (H), as well as on the conditions of the process, such as the air flow, stirring
414 or temperature. In WWTPs, two volatilization processes can be involved: stripping and
415 surface volatilization. In general, the contribution of the volatilization to the overall
416 removal of OMPs is negligible. Only for some compounds, such as the musk fragrance
417 celestolide (ADBI), volatilization has to be taken into account in the mass balances.
418 Suárez et al. (2012), who studied the removal of musk fragrances in a single-sludge
419 nitrification-denitrification plant, observed that around 20-40% of the removal of ADBI
420 was due to stripping, whereas Alvarino et al. (2014) determined a low contribution of
421 volatilization (5-15%) in a CAS unit.

422 Sorption depends on the OMP lipophilic character or its tendency to be ionized or
423 dissociated in aqueous phase (presence of amino or carboxyl groups, etc.), as well as on
424 the physico-chemical characteristics of the sludge (organic compound fraction or particle
425 size) (Verlicchi et al., 2013). Two mechanisms have to be taken into account (Sipma et
426 al., 2010): absorption, that is associated to the hydrophobic interactions between the
427 aliphatic and aromatic groups of a compound with the lipophilic cell membrane of the
428 microorganisms and the fat fractions of the sludge, and adsorption, that refers to the
429 electrostatic interactions of the positively charged groups of the OMPs with the negatively
430 charged surfaces of the microorganisms (Verlicchi et al., 2013). The trend to be absorbed

431 is usually related to the octanol-water coefficient (K_{ow}) (Suárez et al., 2008). Among
432 OMPs characterized by a high K_{ow} are the musk fragrances or fluoxetine (Alvarino et
433 al., 2018; Horsing et al., 2011). In the case of the hydrophobic OMPs, the charge and the
434 molecular size explain their adsorption into the negatively charged biomass (Wunder et
435 al., 2011). This fact explains the higher adsorption of ERY (positively charged) compared
436 to the SMX (negatively charged) (Wunder et al., 2011).

437 Biotransformation in WWTPs is related to the biochemical reactions induced by the
438 presence of microorganisms in water, such as bacteria, which assimilate the pollutants as
439 growth or maintenance substrates leading to their transformation (Tran et al., 2013; Yang
440 et al., 2013). Although complete degradation (biomineralization) can be reached for some
441 OMPs, for most of them the removal efficiencies achieved are only partial, being some
442 compounds completely recalcitrant (Clara et al., 2004; Collado et al., 2014). The study of
443 the metabolites generated as intermediate products is a very useful tool to understand the
444 fate of OMPs in bioprocesses as well as the biochemical reactions and enzymes involved.

445 As previously studied in section 3.2, the degree of OMP biotransformation under the
446 different redox conditions applied during wastewater treatment is very much influenced
447 by the chemical structure of the compounds. Other parameters of the biological processes
448 that play a key role on the OMP fate, include the biomass concentration and activity
449 (heterotrophic aerobic/anoxic/anaerobic, nitrifying), as well as the operational conditions
450 considered (HRT, SRT). Other influencing factors less considered in literature include the
451 bioavailability of the substance to be biotransformed or the fraction of inert matter
452 contained in the sludge. As an overall approach biotransformation is quantified by
453 biological kinetic coefficients (k_{biol}). Normally the mass balances assume pseudo steady-
454 state conditions, a continuous stirred tank reactor model pattern and pseudo-first-order
455 kinetics (Joss et al., 2006; Ternes et al., 2006). The information obtained through this
456 approach is interesting and very useful especially to compare the differences in
457 biotransformation between OMPs. However, the high number of factors involved makes
458 that k_{biol} only gives accurate biotransformation rates under the specific conditions studied,
459 being difficult to extrapolate them to other configurations.

460 The influence of biomass concentration on the value of the kinetic coefficients can be
461 illustrated by the following case study for the anti-inflammatory NPX (Alvarino et al.,
462 2014). The k_{biol} coefficient was determined for this OMP in two reactors: an aerobic CAS
463 unit and an anaerobic UASB reactor, treating the same influent. Although NPX was
464 removed to a high extent in both systems, the calculated k_{biol} in the anaerobic system (1.1
465 $L\ g_{VSS}^{-1}\ d^{-1}$) was much lower than in the CAS unit ($9\ L\ g_{VSS}^{-1}\ d^{-1}$), being this difference
466 related to the biomass concentration (30 and $1.8\ g_{VSS}\ L^{-1}$, respectively).

467

468 **5. Technological concepts for OMPs removal**

469 In the case OMPs removal is aimed due to their possible toxicity and bioaccumulation
470 potential, it should be specifically addressed when conceiving innovative processes. This

471 is especially relevant for wastewaters containing higher amounts of OMPs, such as
472 hospital wastewater (HW) with concentrations of pharmaceuticals 4-150 times higher
473 compared to those present in municipal wastewater (Verlicchi et al., 2010).

474 Processes based on conventional activated sludge (CAS) for carbon and nutrient removal
475 are the most extended technologies implemented in urban WWTPs. They consist of a
476 biological reactor with suspended biomass (or a series of them) followed by a settler.
477 Although these processes are able to readily remove certain OMPs, such as IBP,
478 acetaminophen (PAR), acetylsalicylic acid (ASA), musk fragrances or bisphenol A
479 (BPA), other compounds show a recalcitrant behaviour reaching the final effluents of the
480 WWTPs and thus being discharged into the environment (Gabet-Giraud et al., 2010; Clara
481 et al., 2005a; Carballa et al., 2004). Although there has been a huge development of
482 innovative technologies (hybrid systems considering different redox conditions, biomass
483 configurations, use of membranes, etc.) to address the challenges of achieving more
484 sustainable wastewater treatment in accordance with the current regulations in developed
485 countries (e.g. EU WFD), the removal of OMPs is usually not addressed specifically.

486 In the case of new technological developments targeting OMPs removal, most of the
487 publications are focussed in MBR systems (Park et al., 2017; Reif et al., 2008; Abegglen
488 et al., 2009; Clara et al., 2005), while only few papers considered for instance the
489 anammox-based configurations (Kassotaki et al., 2018, Laurenzi et al., 2016; Alvarino et
490 al., 2015; de Graaf et al., 2011). The first works dealing with OMP removal in MBRs
491 compared to the conventional processes were published in 2005 (Clara et al., 2005a),
492 while the first report of a hybrid process combining the use of supports and suspended
493 biomass can be found in 2008. Three years later, in 2011 the first results were published
494 concerning OMPs behaviour in an anammox-based process (de Graaf et al., 2011).

495 Among the most innovative technological options proposed for increasing OMP removal
496 during secondary wastewater treatment, the following features can be summarised: i) the
497 use of reactors operating at high biomass concentrations and long SRTs; ii) the use of
498 different biomass conformations (biofilms, granular, flocculent); iii) the combination of
499 several redox potentials; iv) the promotion of more specific bacterial populations and v)
500 the addition of adsorbents directly into the mixed liquor of biological reactors. The
501 innovative systems considered in this paper are based on the combination of these new
502 technological options.

503

504 **5.1 Technologies promoting higher biomass retention**

505 *5.1.1 Membrane bioreactors (MBRs)*

506 MBRs are particularly relevant when available space is a serious limitation and water
507 reclamation is an important issue. This technology has some advantages compared to the
508 CAS process, such as the high-quality effluents produced, the low sludge production and
509 the possibility to work at short HRTs (Ng et al., 2007; Stephenson et al., 2000).

510 Additionally, the use of membranes allows increasing the sludge concentration and the
511 SRT applied so that the biomass growth is not restricted to the fast-growing and floc-
512 forming microorganisms (Radjenović et al., 2009; Brepols et al., 2008).

513 Better OMP removal efficiencies in MBR compared to CAS units have been reported in
514 different works (Radjenović et al., 2009; González et al., 2006; Kimura et al., 2005;
515 Quintana et al., 2005). The particular operational conditions of MBRs have shown to
516 enhance the removal of OMPs by sorption, such as in the case of tetracycline,
517 ciprofloxacin (CIP) or ofloxacin (OFL), as well as by biotransformation due to the
518 development of slower growing species (de la Torre et al., 2015; Kim et al., 2007). The
519 consequent reduction of the F/M ratio could benefit biotransformation of the more
520 recalcitrant compounds (De Wever et al., 2007; Clara et al., 2005a). Other authors showed
521 comparable results in MBR and CAS systems if similar operational conditions were
522 applied (Clara et al., 2005a; Joss et al., 2005). Reif et al. (2011) determined higher OMP
523 removals in an MBR compared to a CAS when the SRT was 10 d, whereas the differences
524 were not significant anymore when both systems were operated with an SRT of 20 d.

525 The role of OMP retention by the membrane due to size exclusion is only relevant in the
526 case of nanofiltration or reverse osmosis. Xue et al. (2010) reported a removal of OMPs
527 by sorption into the membrane body and/or on the cake layer. Even OMP retention by
528 size exclusion in the cake layer has been observed (Terzic et al., 2005). Membranes
529 produced with hydrophobic materials have shown significant sorption of OMPs (Jermann
530 et al., 2009).

531

532 *5.1.2 Biofilm reactors*

533 Among the biofilm reactor concept, some alternatives combine suspended and attached
534 biomass, allowing the achievement of high biomass concentrations and SRT compared to
535 CAS systems. The use of supports allows the development of a broader spectrum of
536 microorganisms that could be active in the biotransformation of some OMPs, due to the
537 retention in the system of slow-growing bacteria. This is the case of nitrifiers that were
538 promoted by the use of supports (Di Trapani et al., 2014). Falås et al. (2012) observed a
539 higher removal rate per unit biomass in a biofilm compared to the suspended biomass for
540 DCF, KET, mefenamic acid, gemfibrozil and clofibric acid. The formation of anoxic and
541 anaerobic environments inside the biofilm promoted biotransformation routes under
542 different redox conditions (Alvarino et al., 2017).

543 High removal efficiencies (> 80%) were achieved in moving bed MBRs (MBMBR) for
544 IBP, NPX or ASA, mainly related to the presence of strong electron donating functional
545 groups, such as hydroxyl groups, which enhance the removal of OMPs under aerobic
546 conditions (Luo et al., 2014). This high removal could be related to the ability of the
547 ammonia oxidizing bacteria to oxidize compounds with hydroxyl groups (Fernandez-
548 Fontaina et al., 2012).

549 De la Torre et al. (2015) assessed the removal of OMPs in different reactors operating
550 with suspended and attached biomasses. The best behaviour in terms of OMPs removal
551 was achieved in the IFAS-MBR with average removal efficiencies above 65% due to the
552 combination of both types of biomasses in high concentrations. On the other hand, low
553 removals were observed in the system operated only with attached biomass due to the
554 low biomass concentrations. Arya et al. (2016) reported that a submerged attached
555 biofilter (SABF) was the most effective and robust system to remove OMPs compared to
556 a MBR and a CAS unit, although only slight differences in the effectiveness were
557 observed between the MBR and the SABF.

558

559 **5.2 Combination of different redox conditions**

560 One of the trends in the development of innovative WWTP configurations is the
561 application of different redox potentials to enhance the microbial diversity. The aim is to
562 biotransform a wider range of complex pollutants while maintaining a high degree in the
563 COD and nutrient removal processes (Luo et al., 2014). Aerobic processes are still the
564 most applied in secondary wastewater treatment, despite of their energetic inefficiency.
565 Aeration consumes around 40% of the total electric energy (McCarty et al., 2011), being
566 45 % of the total COD in the raw wastewater lost as carbon dioxide (Guo et al., 2010). A
567 more sustainable alternative consists of applying methanogenic anaerobic digestion,
568 which enables the recovery of energy in the form of biogas (Silvestre et al., 2015), with
569 the consequent reduction in the net energy consumption (Dai et al., 2015). This justifies
570 the progressive installation of new anaerobic methanogenic reactors in the water line
571 followed by aerobic post-treatment steps, in order to promote the valorization of the
572 organic matter contained in wastewaters (Bustillo-Lecompte et al., 2017; Lv et al., 2017;
573 Buntner et al., 2011). The combination of the three redox potentials (anaerobic-anoxic-
574 aerobic) allows achieving complete removal of nutrients, such as nitrogen and
575 phosphorous (Zhang et al., 2016; Liu et al., 2013).

576

577 *5.2.1 Methanogenic anaerobic steps*

578 Most of the available information about the removal of OMPs under anaerobic conditions
579 refers to the sludge line. The application of anaerobic conditions has shown to be positive
580 for the removal of some OMPs, as TMP, SMX and KET, when wastewater is treated in
581 an anaerobic MBR (Monsalvo et al., 2014). Several OMPs, such as diuron, DCF or TMP,
582 require an anaerobic treatment to be biotransformed (Falás et al., 2016). In the case of
583 the hormones E1, E2 and EE2, higher removals were reported under aerobic conditions
584 compared to the results obtained under negative redox potentials in the water line (Zhang
585 et al., 2015; Joss et al., 2004).

586 Alvarino et al. (2016) has studied the removal of OMPs in an methanogenic anaerobic
587 reactor followed by an aerobic MBR post-treatment (anaerobic hybrid MBR process).

588 Biotransformation of OMPs prone to be removed under anaerobic conditions was
589 reported (e.g. TMP or SMX), although most of the OMPs were mainly removed under
590 aerobic conditions.

591

592 *5.2.2 Non methanogenic anaerobic steps*

593 Processes based on MBRs comprising different redox conditions (anaerobic, anoxic and
594 aerobic) for carbon and nutrient removal have gained interest (Silva-Teira et al., 2017;
595 Leyva-Díaz et al., 2016; Hu et al., 2014). In these systems, the internal recirculation (IR)
596 ratio is one of the key operational factors for process optimisation. Phan et al. (2014)
597 studied the removal of 30 OMPs, analyzing the IR rate between the aerobic and the anoxic
598 stages in an anaerobic-anoxic-aerobic process. The supply of nitrate, as well as the
599 dilution, mass transfer and the microaeration in the anoxic chamber are a function of the
600 internal recirculation rate. For 9 OMPs evaluated, such as triclosan, o-nonylphenol (NP)
601 or 17 β -estradiol-17-acetate, removals above 50% were obtained under anaerobic and
602 anoxic conditions without any influence of the IR rate. Negligible removal was observed
603 under anaerobic conditions for 11 OMPs, such as KET, IBP, ASA or formononetin, which
604 were biotransformed to a moderate extent under anoxic conditions. Suárez et al. (2012)
605 studied the effect of the IR in a denitrification-nitrification single sludge unit and reported
606 an improvement in the removal of IBP, NPX, CTL and FLX when the IR to the anoxic
607 stage was increased. The enhancement was related to a more effective mixing and the
608 transport of oxygen from the aerobic to the anoxic chamber. Xue et al. (2010) studied the
609 removal of 19 OMPs in an anaerobic-anoxic-aerobic MBR process and observed a higher
610 OMP elimination in the anaerobic compartment which was linked to several aspects: the
611 rapid adsorption of OMP onto the sludge, the internal recirculation and the presence of
612 readily biotransformable OMPs under anaerobic conditions.

613

614 *5.2.3 Autotrophic nitrogen removal systems*

615 One of the alternatives to conventional nitrification-denitrification is the autotrophic
616 nitrogen removal process due to several advantages: i) lower energy consumption (less
617 aeration is needed), ii) no need of external organic matter addition, iii) lower sludge
618 production and, iv) lower greenhouse gases emissions (N₂O, NO and less CO₂ stripped)
619 (Vázquez-Padín et al., 2014; Kartal et al., 2013, 2008; Okabe et al., 2011; Kuenen, 2008;
620 Ruiz et al., 2006). De Graaf et al. (2011) studied the removal of several OMPs in a partial
621 nitrification-anammox process, observing that IBP was mainly transformed in the
622 anammox process (77%), whereas Falås et al. (2012), following IBP in kinetic batch
623 experiments stated a clear effect of nitrification on its removal. Alvarino et al. (2015)
624 correlated the removal of IBP with the nitritation rate in a nitrification-anammox process,
625 whereas no influence of the anammox activity was observed. In the case of the other anti-
626 inflammatory, such as KTP, NPX or DCF, low removal in an anammox process was
627 reported by Falas et al. (2012). The anammox activity exerts a positive influence on the

628 removal of the antibiotic ERY, being a correlation with the nitrite removal rate reported
629 by Alvarino et al. (2015). A low removal of DCF has been also reported by de Graaf et al.
630 (2011), with efficiencies below 40% in a nitrification-anammox process. This behavior is
631 similar to what has been obtained for DCF in a conventional nitrification-denitrification
632 unit (Suárez et al., 2010). The recalcitrant behavior of CBZ and DZP has been consistently
633 reported for the autotrophic and the heterotrophic biological nitrogen removal processes
634 (Fernandez-Fontaina et al., 2012; de Graaf et al., 2011; Suárez et al., 2010).

635

636 **5.3 The use of adsorbents in biological reactors**

637 Sorption onto granular activated carbon (GAC) has been used conventionally as post-
638 treatment in order to enhance the removal of OMPs after the biological processes (Nguyen
639 et al., 2012). Although these systems are primarily based on the physico-chemical
640 adsorption of the target pollutants, biotransformation can also occur as a result of the
641 development of a biofilm layer on the GAC particles (Paredes et al., 2016; Matamoros et
642 al., 2007). Another strategy consists on the simultaneous promotion of both,
643 physicochemical and biological processes, inside one single reactor. In this sense, Sirotkin
644 et al. (2001) proposed a direct dosing of powdered activated carbon (PAC) into a MBR.
645 This has shown a number of positive effects: i) reduction of membrane fouling (Alvarino
646 et al., 2017); ii) higher removal of conventional pollutants derived from the growth of a
647 biofilm onto the activated carbon particles (Remy et al., 2009; Rice and Robson, 1982);
648 iii) decrease of toxicity caused by certain inhibitors on the nitrification process (Widjaja
649 et al., 2004), and iv) retention of the PAC by the membrane. This direct addition of PAC
650 also showed promising results for OMPs, since high removal efficiencies for the
651 recalcitrant compounds CBZ and DZP were achieved in a sequential batch reactor (SBR)
652 coupled to a membrane filtration tank by Serrano et al. (2011). In such systems, the OMPs
653 are removed either by biotransformation (promoted by the suspended biomass and the
654 biofilm) or by sorption onto the sludge and the PAC. Alvarino et al. (2016c) determined
655 an enhancement of the OMP biotransformations after the direct addition of PAC in an
656 MBR, which was specially relevant for the compounds with moderate biodegradability.

657

658 **6. Metabolism/cometabolism**

659 The OMPs are present in municipal wastewaters at much lower concentrations than the
660 macropollutants (i.e. organic matter and nutrients). Thus, it is expected that a primary
661 substrate is necessary for inducing the enzymes for the OMP biotransformation by means
662 of cometabolism. During this process, the persistent compounds are converted into more
663 biotransformable intermediate products within the global metabolic pathways (Yi and
664 Harper, 2007).

665 In the case of nitrification, several authors reported a simultaneous elimination of
666 ammonia and OMPs, like EE2, IBP, NPX or trichloroethylene (TCE) (Fernandez-

667 Fontaina et al., 2012, Yi and Harper et al., 2007; Yi et al., 2006), through cometabolic
668 biotransformations carried out by autotrophic aerobic bacteria. The ammonia
669 monooxygenase produced by ammonium oxidizing bacteria can easily oxidize straight-
670 chain hydrocarbons through hydroxylation (Hyman et al., 1988). Fernandez-Fontaina et
671 al. (2016) reported a high removal of IBP and NPX under nitrification conditions due to the
672 existence of secondary and tertiary carbons in the linear alkyl chains of these compounds,
673 which are easy targets for nucleophilic attack by the AMO enzyme (Fig. 6). Yi and Harper
674 (2007) reported a correlation between nitrification and the removal of the hormone EE2.
675 They showed that the single aromatic ring of EE2 is the site of electrophilic initiating
676 reactions because the frontier electron density of this carbon ring unit is higher than in
677 the case of the other rings and that the pi electrons associated with this ring are sterically
678 unhindered. Therefore, the ring cleavage was observed first in the aromatic ring of the
679 hydroxylated EE2. In presence of the *Sphingobacterium sp.*, Haiyan et al. (2007)
680 proposed another metabolic route, where EE2 is initially oxidized to E1. This pathway
681 continues with the ring cleavage of the ring B, leaving the aromatic ring initially intact.

682 The presence of an external carbon source can lead to an enhancement in the removal of
683 several OMPs, evidencing cometabolism for heterotrophic bacteria. Majewski et al.
684 (2011) determined faster OMP removal efficiencies in the presence of a high number of
685 active heterotrophs when a low SRT was applied. In the case of the antibiotic SMX, a
686 clear positive effect on its removal under aerobic conditions was reported when an
687 external biodegradable carbon source was added to the reactor with the aim of providing
688 enough energy for biomass growth (Fernandez-Fontaina et al., 2016; Müller et al., 2013).
689 The presence of heterocycles and amines, as well as the lack of alkyl side chains, hampers
690 the biotransformation of SMX by the AMO enzyme (Boethling et al., 1994).

691 The positive effect of the presence of heterotrophs was also demonstrated by Larcher and
692 Yargeau (2013) for EE2 biotransformation, for which medium-high removal efficiencies
693 were determined when using several heterotrophic pure cultures (*B. subtilis*, *P.*
694 *aeruginosa*, *P. putida*, *R. equi*, *R. erythropolis*, *R. rhodochrous*, *R. zopfii*). In the case of
695 the pure culture *R. rhodochrous* even a total removal was achieved. Other studies on the
696 synthetic hormone EE2 reported its biotransformation by both, heterotrophic and
697 autotrophic bacteria (Larcher and Yargeau, 2013; Khunjar et al., 2011; Yi and Harper,
698 2007).

699 Fernandez-Fontaina et al. (2016) applied two cosubstrates alternatively (ammonium or
700 organic matter) in order to determine their cometabolic effect on the removal of a selected
701 group of OMPs, observing efficient removals (> 80%) of the antibiotics ERY and ROX
702 independently of the cosubstrate used. Tran et al. (2009) studied the cometabolic removal
703 of OMPs by the addition of several growth substrates (ammonium and organic substrates).
704 It was observed that for most of the OMPs higher removal efficiencies were obtained by
705 the use of growth substrates due to the induction of the activity of the specific enzymes
706 involved in each process. These authors identified a cometabolic biotransformation of
707 IBP (> 75%) and to a less extent of NPX, DCF, KET, fenoprofen (FEN) or gemfibrozil

708 (GEM), by the heterotrophic bacteria when a nitrification inhibitor (allylthiourea) was
709 added.

710 Information about the OMP cometabolism under anaerobic conditions is scarce.
711 Gonzalez-Gil et al. (2017) studied the cometabolic biotransformation of 20 OMPs during
712 methanogenesis. The process key enzyme acetate kinase has shown to be able to
713 biotransform OMPs that contain a carboxyl or hydroxyl group and have moderate steric
714 hindrances, such as naproxen, nonylphenol, octylphenol or bisphenol A.

715 In the case of primary metabolism, the presence of the OMPs in sufficient concentrations
716 is necessary for allowing the growth and maintenance of the sludge, as well as for the
717 production of the enzymes and cofactors responsible for the OMP biotransformations
718 (Tran et al., 2013). Müller et al. (2013) studied the biotransformation of SMX under
719 aerobic conditions (50 mg L^{-1}) and determined that the sludge communities were able to
720 use SMX both as energy supply and for growth support. More concretely, heterotrophic
721 bacteria assimilated SMX as a carbon source, while autotrophic bacteria used SMX as N
722 source. Other authors assessed the OMP biotransformations when being the sole available
723 carbon source in pure cultures. For instance, *Sphingomonas Ibu-2* was capable of
724 biotransforming IBP by metabolism (Murdoch and Hay, 2005), while *Pseudomonas*
725 *aeruginosa TJI* and *Novosphingobium JEM-1* were able to oxidize E2 (Iasur-Kruh et al.,
726 2011; Zeng et al., 2009).

727

728 **Conclusions**

729 The interest of the scientific community on OMPs in wastewater in the last 17 years
730 clearly focused on pharmaceuticals compared to other groups such as pesticides, PCPs or
731 EDCs. The studies on the fate of these compounds has been increasing significantly
732 according to the bibliometric study provided in this paper, moving from 38 scientific
733 papers written by groups belonging to 14 countries in the period 2001-05 up to 264
734 articles by groups from 44 countries in 2011-15. Only in the last two years, 2016-2017,
735 138 articles were published by groups from 42 countries, with an increasing participation
736 of developing countries all over the world. Not only the number of countries working on
737 these issues has been increasing, but also the number of collaborations between research
738 groups from different countries. As a result of this effort, the first regulations have
739 recently started to appear (Switzerland) or are under discussion (USA, EU zone).

740 The trend in the study of OMPs during the secondary treatment of sewage has been
741 moving from a general overview on the fate, to more specific works that analyse the
742 contribution of different mechanisms on the OMP removal efficiencies. There is enough
743 information available in bibliography in order to confirm the influence of different
744 operational parameters on the removal of OMPs. This includes HRT, SRT and redox
745 conditions as most frequently studied parameters, but other aspects as the biomass
746 concentration and activity play also an important role on the results achieved.

747 In the last years, new advanced wastewater treatment technologies have been developed
748 in order to achieve more sustainable processes using a holistic approach. Although OMPs
749 removal has not been usually present in these considerations, the situation is changing as
750 new processes are already featuring enhanced OMPs removals. In the last 17 years the
751 11% of publications on the fate of pharmaceuticals in wastewater tackled specifically
752 technological aspects. Currently most of these works still focus on the differences
753 between CAS and MBRs.

754 OMPs are normally removed by cometabolism due to their low concentrations in
755 municipal wastewaters compared to macropollutants. This implies that the metabolic
756 route for OMPs biotransformation is a function of the primary metabolic activity and the
757 microbial diversity, besides the other operational conditions. Still very few studies have
758 provided insights on these relations.

759 This review clearly demonstrates that pharmaceuticals in wastewater constitute a hot
760 topic all around the world. An outstanding progress has been made since 2000 in
761 determining the fate and main removal mechanisms of these compounds during
762 wastewater treatment. However there are still important knowledge gaps that should be
763 further studied in order to reach the desirable removal efficiencies during secondary
764 wastewater treatments. The new technological options developed to achieve better results
765 in terms of OMP removal should consider, besides working under different redox
766 conditions, other factors such as the use of different biomass conformations and/or the
767 addition of adsorbents into biological reactors. More information is needed about the
768 cometabolic biotransformations of OMPs, since this would allow to adapt the primary
769 metabolism to conditions favourable to the removal of these substances.

770

771 **Acknowledgement**

772 **Funding:** This research was supported by the Ministerio de Economía y Competitividad
773 (AEI) through the Project COMETT (CTQ2016-80847-R). The authors belong to the
774 Galician Competitive Research Group GRC2013-032 and to the CRETUS Strategic
775 Partnership (AGRUP2015/02). All these programs and project are co-funded by FEDER
776 (UE).

777 **Conflict of Interest:** The authors declare that they have no conflict of interest.

778 **References**

- 779 Abegglen, C., Joss, A., McArdell, C.S., Fink, G., Schlüsener, M.P., Ternes, T.A., Siegrist,
780 H., 2009. The fate of selected micropollutants in a single-house MBR. *Water Res.* 43,
781 2036-2046.
- 782 Adrian, N.R., Suflita, Ú.M., 1994. Anaerobic biodegradation of halogenated and
783 nonhalogenated N-, S-, and O-heterocyclic compounds in aquifer slurries.
784 *Environ.Toxicol. Chem.* 13, 1551-1557.

785 Alvarino, T., Suarez, S., Lema, J., Omil, F., 2018. Understanding the sorption and
786 biotransformation of organic micropollutants in innovative biological wastewater
787 treatment technologies. *Sci. Total Environ.* 615, 297-306.

788 Alvarino, T., Torregrosa, N., Omil, F., Lema, J.M., Suarez, S., 2017. Assessing the
789 feasibility of two hybrid MBR systems using PAC for removing macro and
790 micropollutants. *J. Environ. Manage.* 203, 831-837.

791 Alvarino, T., Suarez, S., Garrido, J.M., Lema, J.M., Omil, 2016a. A UASB reactor
792 coupled to a hybrid aerobic MBR as innovative plant configuration to enhance the
793 removal of organic micropollutants. *Chemosphere* 144, 452-458.

794 Alvarino, T., Naslod, P, Suarez, S., Omil, F., Corvini, P.F.X., Bouju, H., 2016b. Role of
795 biotransformation, sorption and mineralization of 14C-labelled sulfamethoxazole under
796 different redox conditions. *Sci. Total Environ.* 542, 706-715.

797 Alvarino, T., Komesli, O., Suarez, S., Lema, J.M., Omil, F., 2016c. The potential of the
798 innovative SeMPAC process for enhancing the removal of recalcitrant organic
799 micropollutants. *J. Hazard. Mater.* 308, 29-36.

800 Alvarino, T., Suarez, S., Lema, 623 J.M., Omil, F., 2014. Understanding the removal
801 mechanisms of PPCPs and the influence of main technological parameters in anaerobic
802 UASB and aerobic CAS reactors. *J. Hazard. Mater.* 278, 506-513.

803 Arp, D.J., Yeager, C.M., Hyman, M.R., 2001. Molecular and cellular fundamentals of
804 aerobic cometabolism of trichloroethylene. *Biodegradation* 12, 81–103.

805 Arya, V., Philip, L, Bhallamudi, S.M., 2016 .Performance of suspended and attached
806 growth bioreactors for the removal of cationic and anionic pharmaceuticals. *Chem. Eng.*
807 *J.* 284, 1295–1307.

808 Banzhaf, S., Nödler, K., Licha, T., Krein, A., Scheytt, T., 2012. Redox-sensitivity and
809 mobility of selected pharmaceutical compounds in a low flow column experiment. *Sci.*
810 *Total Environ.* 438(2-3), 113-121.

811 Baronti, C., Curini, R., D’Ascenzo, G., Di Corcia, A., Gentili, A., Samperi, R. 2000.
812 Monitoring natural and synthetic estrogens at activated sludge sewage treatment plants
813 and in a receiving river water. *Environ. Sci. Technol.* 34, 5059–5066.

814 Behera, S.K., Kim, H.W., Oh, J-E., Park, H-S., 2011. Occurrence and removal of
815 antibiotics, hormones and several other pharmaceuticals in wastewater treatment plants
816 of the largest industrial city of Korea. *Sci. Total Environ.* 409, 4351–4360.

817 Belhaj, D., Baccar, R., Jaabiri, I., Bouzid, J., Kallel, M., Ayadi, H., Zhou, J.L., 2008. Fate
818 of selected estrogenic hormones in an urban sewage treatment plant in Tunisia (North
819 Africa). *Sci. Total Environ.* 505, 154-160.

820 Besse, J-P., Kausch-Barreto, C., Garric, J., 2008. Exposure assessment of pharmaceuticals
821 and their metabolites in the aquatic environment: Application to the French situation and
822 preliminary prioritization. *Hum. Ecol. Risk Assess.* 14(4), 665-695.

823 Bester, K., 2005. Polycyclic musks in the Ruhr catchment area - Transport, discharges of
824 waste water and transformations of HHCB, AHTN and HHCB-lactone. *J. Environ. Monit.*
825 7, 43-51.

826 Boethling, R. S.; Sommer, E. and DiFiore, D., 2007. Designing small molecules for
827 biodegradability. *Chem. Rev.* 107, 2207-2227.

828 Boethling, R.S., Howard, P.H., Meylan, W., Stiteler, W., Beauman, J., Tirado, N., 1994.
829 Group contribution method for predicting probability and rate of aerobic biodegradation.
830 *Environ. Sci. Technol.* 28(3), 459-465.

831 Brepols, Ch., Dorgeloh, E., Frechen, F.-B., Fuchs, W., Haider, S., Joss, A., de Korte, K.,
832 Ruiken, Ch., Schier, W., van der Roest, H., Wett, M., Wozniak, Th., 2008. Upgrading and
833 retrofitting of municipal wastewater treatment plants by means of membrane bioreactor
834 (MBR) technology. *Desalination* 231(1-3), 20–26.

835 Buntner, D., Sánchez, A., Garrido, J.M., 2011. Three stages MBR (methanogenic, aerobic
836 biofilm and membrane filtration) for the treatment of low-strength wastewaters. *Water*
837 *Sci. Technol.* 64(2), 397-402.

838 Burke, V., Richter, D., Hass, U., Duennbier, U., Greskowiak, J., Massmann, G., 2014.
839 Redox-dependent removal of 27 organic trace pollutants: compilation of results from tank
840 aeration experiments. *Environ. Earth Sci.* 71, 3685–3695.

841 Buser, H-R., Poiger, T., Müller, M.D., 1998. Occurrence and Fate of the Pharmaceutical
842 Drug Diclofenac in Surface Waters: Rapid Photodegradation in a Lake. *Environ. Sci.*
843 *Technol.* 32(22), 3449–3456.

844 Bustillo-Lecompte, C.F., Mehrvar, M., 2017. Treatment of actual slaughterhouse
845 wastewater by combined anaerobic-aerobic processes for biogas generation and removal
846 of organics and nutrients: An optimization study towards a cleaner production in the meat
847 processing industry. *J. Clean. Prod.* 141, 278-289.

848 Carballa, M., Omil, F., Lema, J.M., 2007. Calculation methods to perform mass balances
849 of micropollutants in Sewage Treatment Plants. Application to Pharmaceutical and
850 Personal Care Products (PPCPs). *Environ. Sci. Technol.* 41(3), 884-890.

851 Carballa, M., Omil, F., Lema, J.M., Llompart, M., García-Jares, C., Rodríguez, I., Gómez,
852 M., Ternes, T., 2004. Behavior of pharmaceuticals, cosmetics and hormones in a sewage
853 treatment plant. *Water Res.* 38(12), 2918-2926.

854 Chang, S.W., 1997. Cometabolic degradation of polycyclic aromatic hydrocarbons
855 (PAHs) and aromatic ethers by phenol- and ammonia-oxidizing bacteria, PhD thesis,
856 University of Oregon State.

857 Clara, M., Gans, O., Windhofer, G., Krenn, U., Hartl, W., Braun, K., Scharf, S.,
858 Scheffknecht, C., 2011. Occurrence of polycyclic musks in wastewater and receiving
859 water bodies and fate during wastewater treatment. *Chemosphere* 82(8), 1116-1123.

860 Clara, M., Strenn, B., Gans, O., Martinez, E., Kreuzinger, N., Kroiss, H., 2005a. Removal
861 of selected pharmaceuticals, fragrances and endocrine disrupting compounds in a
862 membrane bioreactor and conventional wastewater treatment plants. *Water Res.* 39(19),
863 4797-4807.

864 Clara, M., Kreuzinger, N., Strenn, B., Gans, O., Kroiss, H., 2005b. The solids retention
865 time – a suitable design parameter to evaluate the capacity of wastewater treatment plants
866 to remove micropollutants. *Water Res.* 39(1), 97-106.

867 Clara, M., Strenn, B., Kreuzinger, N., 2004. Carbamazepine as a possible anthropogenic
868 marker in the aquatic environment: investigations on the behaviour of Carbamazepine in
869 wastewater treatment and during groundwater infiltration. *Water Res.* 38, 947–954.

870 Collado, N., Rodriguez-Mozaz, S., Gros, M., Rubirola, A., Barceló, D., Comas, J.,
871 Rodriguez-Roda, I., Buttiglieri, G., 2014. Pharmaceuticals occurrence in a WWTP with
872 significant industrial contribution and its input into the river system. *Environ Pollut.* 185,
873 202-212.

874 Dai, W., Xu, X., Liu, B., Yang, F., 2015. Toward energy-neutral wastewater treatment: A
875 membrane combined process of anaerobic digestion and nitrification–anammox for biogas
876 recovery and nitrogen removal. *Chem. Eng. J.* 279, 725-734.

877 de Graaff, M.S., Vieno, N.M., Kujawa-Roeleveld, K., Zeeman, G., Temmink, H.,
878 Buisman, C.J.N., 2011. Fate of hormones and pharmaceuticals during combined
879 anaerobic treatment and nitrogen removal by partial nitrification-anammox in vacuum
880 collected black water. *Water Res.* 45(1), 375-383.

881 de la Torre, T., Alonso, E., Santos, J.L., Rodríguez, C., Gómez, M.A., Malfeito, J.J., 2015.
882 Trace organics removal using three membrane bioreactor configurations: MBR, IFAS-
883 MBR and MBMBR. *Water Sci. Technol.* 71(5), 761-768.

884 de Mes, T., Zeeman, G., Lettinga, G., 2005. Occurrence and Fate of Estrone, 17 β -estradiol
885 and 17 α -ethynylestradiol in STPs for Domestic Wastewater. *Rev. Environ. Sci.*
886 *Biotechnol.* 4(4), 275-311.

887 De Wever, H., Weiss, S., Reemtsma, T., Vereecken, J., Müller, J., Knepper, T., Rörden,
888 O., Gonzalez, S., Barcelo, D., Dolores Hernando, M., 2007. Comparison of sulfonated
889 and other micropollutants removal in membrane bioreactor and conventional wastewater
890 treatment. *Water Res.* 41(4), 935-945.

891 Di Trapani, D., Di Bella, G., Mannina, G., Torregrossa, M., Viviani, G., 2014.
892 Comparison between moving bed-membrane bioreactor (MB-MBR) and membrane
893 bioreactor (MBR) systems: influence of wastewater salinity variation. *Bioresour Technol.*
894 162, 60-9.

895 Dorival-García, N., Zafra-Gómez, A., Navalón, A., González-López, J., Hontoria, E.,
896 Vílchez, J.L., 2013. Removal and degradation characteristics of quinolone antibiotics in

897 laboratory scale activated sludge reactors under aerobic, nitrifying and anoxic conditions.
898 J. Environ. Manage. 120, 75-83.

899 Dutta, K., Lee, M.Y., Lai, W.W., Lee, C.H., Lin, A.Y., Lin, C.F., Lin, J.G., 2014. Removal
900 of pharmaceuticals and organic matter from municipal wastewater using two-stage
901 anaerobic fluidized membrane bioreactor. *Bioresour. Technol.* 165, 42-49.

902 Eguchi, K., Nagase, H., Ozawa, M., Endoh, Y.S., Goto, K., Hirata, K., Miyamoto, K.,
903 Yoshimura, H., 2004. Evaluation of antimicrobial agents for veterinary use in the
904 ecotoxicity test using microalgae. *Chemosphere* 57(11), 1733-1738.

905 Ellis, J.B., 2006. Pharmaceutical and personal care products (PPCPs) in urban receiving
906 waters. *Environ. Pollut.* 144(1), 184-189.

907 Escolà Casas, M., Chhetri, R.K., Ooi, G., Hansen, K.M., Litty, K., Christensson, M.,
908 Kragelund, C., Andersen, H.R., Bester, K., 2015. Biodegradation of pharmaceuticals in
909 hospital wastewater by a hybrid biofilm and activated sludge system (Hybas). *Sci. Total*
910 *Environ.* 530-531, 383-392.

911 Falås, P., Wick, A., Castronovo, S., Habermacher, J., Ternes, T.A., Joss, A., 2016. Tracing
912 the limits of organic micropollutant removal in biological wastewater treatment. *Water*
913 *Res.* 95, 240-249.

914 Falås, P., Longrée, P., la Cour Jansen, J., Siegrist, H., Hollender, J., Joss, A., 2013.
915 Micropollutant removal by attached and suspended growth in a hybrid biofilm-activated
916 sludge process. *Water Res.* 47(13), 4498-4506.

917 Falås, P., Baillon-Dhumez, A., Andersen, H.R., Ledin, A., la Cour Jansen, J., 2012.
918 Suspended biofilm carrier and activated sludge removal of acidic pharmaceuticals. *Water*
919 *Res.* 46(4), 1167-1175.

920 Federal Office for the Environment FOEN. c2015. Switzerland: Swiss Confederation;
921 [accessed 2017 Nov 11]. [https:// www.bafu.admin.ch](https://www.bafu.admin.ch)

922 Fernandez-Fontaina, E., Gomes, I.B., Aga, D.S., Omil, F., Lema, J.M., Carballa, M.,
923 2016. Biotransformation of pharmaceuticals under nitrification, nitratation and
924 heterotrophic conditions. *Sci. Total Environ.* 541, 1439-1447.

925 Fernandez-Fontaina, E., Omil, F., Lema, J.M., Carballa, M., 2012. Influence of nitrifying
926 conditions on the biodegradation and sorption of emerging micropollutants. *Water Res.*
927 46(16), 5434-5444.

928 Field, J.A., 2002. Anaerobic degradation of xenobiotic compounds. VII Latin America
929 Workshop and Symposium on Anaerobic Digestion.

930 Gabet-Giraud, V., Miège, C., Choubert, J.M., Ruel, S.M., Coquery, M., 2010. Occurrence
931 and removal of estrogens and beta blockers by various processes in wastewater treatment
932 plants. *Sci. Total Environ.* 408(19), 4257-4269.

- 933 Gerrity, D., Gamage, S., Holady, J.C., Mawhinney, D.B., Quiñones, O., Trenholm, R.A.,
934 Snyder, S.A., 2011. Pilot-scale evaluation of ozone and biological activated carbon for
935 trace organic contaminant mitigation and disinfection. *Water Res.* 45(5), 2155-2165.
- 936 Göbel, A., McArdell, C.S., Joss, A., Siegrist, H., Giger, W., 2007. Fate of sulfonamides,
937 macrolides, and trimethoprim in different wastewater treatment technologies. *Sci. Total*
938 *Environ.* 372 (2-3), 361–371.
- 939 Gómez, M.J., Martínez Bueno, M.J., Lacorte, S., Fernández-Alba, A.R., Agüera, A.,
940 2007. Pilot survey monitoring pharmaceuticals and related compounds in a sewage
941 treatment plant located on the Mediterranean coast. *Chemosphere* 66, 993-1002.
- 942 Gonzalez-Gil, L., Carballa, M., Lema, J.M., 2017. Cometabolic Enzymatic
943 Transformation of Organic Micropollutants under Methanogenic Conditions. *Environ.*
944 *Sci. Technol.* 51(5), 2963–2971.
- 945 González, S., Müller, J., Petrovic, M., Barceló, D. and Knepper, T.P., 2006.
946 Biodegradation studies of selected priority acidic pesticides and diclofenac in different
947 bioreactors. *Environ. Pollut.* 144(3), 926-932.
- 948 Guo, J., Peng, Y., Huang, H., Wang, S., Ge, S., Zhang, J., Wang, Z., 2010. Short- and
949 longterm effects of temperature on partial nitrification in a sequencing batch reactor
950 treating domestic wastewater. *J Hazard Mater.* 179(1-3), 471-479.
- 951 Helbling, D.E., Hollender, J., Kohler, H.P., Fenner, K., 2010. Structure-based
952 interpretation of biotransformation pathways of amide-containing compounds in sludge-
953 seeded bioreactors. *Environ. Sci. Technol.* 44(17), 6628-6635.
- 954 Hirai, N., Nanba, A., Koshio, M., Kondo, T., Morita, M., Tatarazako, N., 2006.
955 Feminization of Japanese medaka (*Oryzias latipes*) exposed to 17 β -estradiol: effect of
956 exposure period on spawning performance in sex-transformed females. *Aquat. Toxicol.*
957 79(3), 288-295.
- 958 Hirsch, R., Ternes, T.A., Haberer, K., Mehlich, A., Ballwanz, F., Kratz, K.L., 1998.
959 Determination of antibiotics in different water compartments via liquid chromatography-
960 electrospray tandem mass spectrometry. *J Chromatogr A.* 815(2), 213-223.
- 961 Hoeger, B., Köllner, B., Dietrich, D.R., Hitzfeld, B., 2005. Water-borne diclofenac affects
962 kidney and gill integrity and selected immune parameters in brown trout (*Salmo trutta f.*
963 *fario*). *Aquat. Toxicol.* 75(1), 53-64.
- 964 Hu, X., Xie, L., Shim, H., Zhang, S., Yang, D., 2014. Biological Nutrient Removal in a
965 Full Scale Anoxic/Anaerobic/Aerobic/ Pre-anoxic-MBR Plant for Low C/N Ratio
966 Municipal Wastewater Treatment. *Chin. J. Chem. Eng.* 22(4), 447-454.
- 967 Huppert, N., Würtele, M., Hahn, H.H., 1998. Determination of the plasticizer
968 Nbutylbenzenesulfonamide and the pharmaceutical Ibuprofen in wastewater using solid
969 phase microextraction (SPME). *Fresenius J. Anal. Chem.* 362, 529–536.

970 Hyman, M.R., Murton, I.B., Arp, D.J., 1988. Interaction of ammonia monooxygenase
971 from *Nitrosomonas europaea* with alkanes, alkenes and alkynes. . *Environ. Microbiol.*
972 54(12), 3187-3190.

973 Iasur-Kruh, L., Hadar, Y., Minz, D., 2011. Isolation and Bioaugmentation of an Estradiol-
974 Degrading Bacterium and Its Integration into a Mature Biofilm. *Appl. Environ.*
975 *Microbiol.* 77(11), 3734–3740.

976 Jermann, D., Pronk, W., Boller, M., Schäfer, A.I., 2009. The role of NOM fouling for the
977 retention of estradiol and ibuprofen during ultrafiltration. *J. Membr. Sci.* 329(1-2), 75–
978 84.

979 Jewell, K.S., Castronovo, S., Wick, A., Falås, P., Joss, A., Ternes, T.A., 2016. New
980 insights into the transformation of trimethoprim during biological wastewater treatment.
981 *Water Res.* 88, 550-557.

982 Joss, A., Zabczynski, S., Gobel, A., Hoffmann, B., Löffler, D., McArdell, C.S., Ternes,
983 T.A., Thomsen, A., Siegrist, H., 2006. Biological degradation of pharmaceuticals in
984 municipal wastewater treatment: proposing a classification scheme. *Water Res.* 40(8),
985 1686–1696.

986 Joss, A., Keller, E., Alder, A.C., Göbel, A., McArdell, C.S., Ternes, T., Siegrist, H., 2005.
987 Removal of pharmaceuticals and fragrances in biological wastewater treatment. *Water*
988 *Res.* 39(14), 3139–3152.

989 Joss, A. , Ternes, H.A., Richle, P., Siegrist, H., 2004. Removal of estrogens in municipal
990 wastewater treatment under aerobic and anaerobic conditions: consequences for plant
991 optimization. *Environ. Sci. Technol.* 38(11), 3047-3055.

992 Haiyan, R., Shulan, J., ud din Ahmad, N., Dao, W., Chengwu, C., 2007. Degradation
993 characteristics and metabolic pathway of 17 α -ethinylestradiol by *Sphingobacterium* sp.
994 JCR5. *Chemosphere* 66, 340–346.

995 Kassotaki, E., Pijuan, M., Joss, A., Borrego, C.M., Rodriguez-Roda, I., Buttiglieri, G.,
996 2018. Unraveling the potential of a combined nitrification-anammox biomass towards the
997 biodegradation of pharmaceutically active compounds. *Sci Total Environ.* 624, 722-731.

998 Kartal, B., de Almeida, N.M., Maalcke, W.J., Op den Camp, H.J., Jetten, M.S., Keltjens,
999 J.T., 2013. How to make a living from anaerobic ammonium oxidation. *FEMS Microbiol.*
1000 *Rev.* 37(3), 428-461.

1001 Kasprzyk-Hordern, B., Dinsdale, R.M., Guwy, A.J., 2009. The removal of
1002 pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during
1003 wastewater treatment and its impact on the quality of receiving waters. *Water Res.* 43(2),
1004 363-380.

1005 Keener, W.K., Arp, D.J., 1993. Kinetic studies of Ammonia Monooxygenase inhibition in
1006 *Nitrosomonas europaea* by hydrocarbons and halogenated hydrocarbons in an optimized
1007 whole-cell assay. *Appl. Environ. Microbiol.* 59(8), 2501–2510.

- 1008 Khunjar, W.O., Mackintosh, S.A., Skotnicka-Pitak, J., Baik, S., Aga, D.S., Love, N.G.,
1009 2011. Elucidating the relative roles of ammonia oxidizing and heterotrophic bacteria
1010 during the biotransformation of 17 α -ethinylestradiol and trimethoprim. *Environ. Sci.*
1011 *Technol.* 45(8), 3605-3612.
- 1012 Kim, S.D., Cho, J., Kim, I.S., Vanderford, B.J., Snyder, S.A., 2007. Occurrence and
1013 removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking
1014 and waste waters. *Water Res.* 41, 1013-1021.
- 1015 Kimura, K., Hara, H., Watanabe, Y., 2005. Removal of pharmaceutical compounds by
1016 submerged membrane bioreactors (MBRs). *Desalination* 178(1-3), 135-140.
- 1017 Knackmuss, H.J., 1996. Basic knowledge and perspectives of bioelimination of
1018 xenobiotics compounds. *J. Biotechnol.* 51(3), 287–295.
- 1019 Kolpin, D.W., Skopec, M., Meyer, M.T., Furlong, E.T., Zaugg, S.D., 2004. Urban
1020 contribution of pharmaceuticals and other organic wastewater contaminants to streams
1021 during differing flow conditions. *Sci. Total Environ.* 328(1-3), 119-130.
- 1022 Kovalova, L., Siegrist, H., von Gunten, U., Eugster, J., Hagenbuch, M., Wittmer, A.,
1023 Moser, R., McArdell, C.S., 2013. Elimination of micropollutants during post-treatment
1024 of hospital wastewater with powdered activated carbon, ozone, and UV. *Environ. Sci.*
1025 *Technol.* 47(14), 7899-7908.
- 1026 Kuenen, J.G., 2008. Anammox bacteria: from discovery to application. *Nat. Rev.*
1027 *Microbiol* 6, 320–326.
- 1028 Kupper, T., Plagellat, C., Brändli, R.C., De Alencastro, L.F., Grandjean, D., Tarradellas,
1029 J., 2006. Fate and removal of polycyclic musks, UV filters and biocides during
1030 wastewater treatment. *Water Res.* 40(14), 2603-2612.
- 1031 Larcher, S., Yargeau, V., 2013. Biodegradation of 17 α -ethinylestradiol by heterotrophic
1032 bacteria. *Environ. Pollut.* 173, 17-22.
- 1033 Laurenzi, M., Falàs, P., Robin, O., Wick, A., Weissbrodt, D.G., Nielsen, J.L., Ternes, T.A.,
1034 Morgenroth, E., Joss, A., 2016. Mainstream partial nitrification and anammox: long-term
1035 process stability and effluent quality at low temperatures. *Water Res.* 101, 628-639.
- 1036 Leyva-Díaz, J.C., Muñío, M.M., González-López, J., Poyatos, J.M., 2016.
1037 Anaerobic/anoxic/oxic configuration in hybrid moving bed biofilm reactor-membrane
1038 bioreactor for nutrient removal from municipal wastewater. *Ecol. Eng.* 91, 449-458.
- 1039 Lin, A.Y., Lin, C., Tsai, Y., 2010. Fate of selected pharmaceuticals and personal care
1040 products after secondary wastewater treatment processes in Taiwan. *Water Sci. Technol.*
1041 62(10), 2450–2458.
- 1042 Liu, G., Xu, X., Zhu, L., Xing, S., Chen, J., 2013. Biological nutrient removal in a
1043 continuous anaerobic–aerobic–anoxic process treating synthetic domestic wastewater.
1044 *Chem. Eng. J.* 225, 223-229.

- 1045 Lu, J., Jin, Q., He, Y., Wu, J., Zhang, W., Zhao, J., 2008. Anaerobic degradation behavior
1046 of nonylphenol polyethoxylates in sludge. *Chemosphere* 71, 345-351.
- 1047 Lu, J., Jin, Q., He, Y.L., Wu, J., 2007. Biodegradation of nonylphenol polyethoxylates
1048 under Fe(III)-reducing conditions. *Chemosphere* 69, 1047–1054.
- 1049 Luo, Y., Guo, W., Ngo, H.H., Nghiem, L.D., Hai, F.I., Zhang, J., Liang, S., Wang, X.C.,
1050 2014. A review on the occurrence of micropollutants in the aquatic environment and their
1051 fate and removal during wastewater treatment. *Sci. Total Environ.* 473-474, 619-641.
- 1052 Lv, L., Li, W., Wu, C., Meng, L., Qin, W., 2017. Microbial community composition and
1053 function in a pilot-scale anaerobic-anoxic-aerobic combined process for the treatment of
1054 traditional Chinese medicine wastewater. *Bioresour. Technol.* 240, 84-93.
- 1055 Maeng, S.K., Choi, B.G., Lee, K.T., Song, K.G., 2013. Influences of solid retention time,
1056 nitrification and microbial activity on the attenuation of pharmaceuticals and estrogens in
1057 membrane bioreactors. *Water Res.* 47(9), 3151-3162.
- 1058 Majewsky, M., Gallé, T., Yargeau, V., Fischer, K., 2011. Active heterotrophic biomass
1059 and sludge retention time (SRT) as determining factors for biodegradation kinetics of
1060 pharmaceuticals in activated sludge. *Bioresour. Technol.* 102(16), 7415-7421.
- 1061 Margot, J., Kienle, C., Magnet, A., Weil, M., Rossi, L., de Alencastro, L.F., Abegglen, C.,
1062 Thonney, D., Chèvre, N., Schärer, M. and Barry D.A., 2013. Treatment of micropollutants
1063 in municipal wastewater: Ozone or powdered activated carbon?. *Sci. Total Environ.* 461-
1064 462, 480-498.
- 1065 Matamoros, V., Arias, C., Brix, H., Bayona, J.M., 2007. Removal of pharmaceuticals and
1066 personal care products (PPCPs) from urban wastewater in a pilot vertical flow constructed
1067 wetland and a sand filter. *Environ. Sci. Technol.* 41(23), 8171-8177.
- 1068 Maurer, M., Escher, B.I., Richle, P., Schaffner, C., Alder, A.C., 2007. Elimination of
1069 [beta]-blockers in sewage treatment plants. *Water Res.* 41, 1614–1622.
- 1070 McAvoy, D.C., Schatowitz, B., Jacob, M., Hauk, A., Eckhoff, W.S., 2002. Measurement
1071 of triclosan in wastewater treatment systems. *Environ. Toxicol. Chem.* 21(7), 1323-1329.
- 1072 McCarty, P.L., Bae, J., Kim, J., 2011. Domestic wastewater treatment as a net energy
1073 producer – can this be achieved? *Environ. Sci. Technol.* 45(17), 7100–7106.
- 1074 Miège, C., Choubert, J.M., Ribeiro, L., Eusebe, M., Coquery, M., 2009. Fate of
1075 pharmaceuticals and personal care products in wastewater treatment plants – Conception
1076 of a database and first results. *Environ. Pollut.* 157(5), 1721-1726.
- 1077 Monsalvo, V.M., McDonald, J.A., Khan, S.J., Le-Clech, P., 2014. Removal of trace
1078 organics by anaerobic membrane bioreactors. *Water Res.* 49, 103-112.
- 1079 Müller, E., Schüssler, W., Horn, H., Lemmer, H., 2013. Aerobic biodegradation of the
1080 sulfonamide antibiotic sulfamethoxazole by activated sludge applied as co-substrate and
1081 sole carbon and nitrogen source. *Chemosphere* 92 (8), 969–978.

- 1082 Murdoch, R.W., Hay, A.G., 2005. Formation of catechols via removal of acid side chains
1083 from ibuprofen and related aromatic acids. *Appl. Environ. Microbiol.* 71(10), 6121-6125.
- 1084 Musolff, A., Leschik, S., Möder, M., Strauch, G., Reinstorf, F., Schirmer, M., 2009.
1085 Temporal and spatial patterns of micropollutants in urban receiving waters. *Environ.*
1086 *Pollut.* 157(11), 3069-3077.
- 1087 Musson, S.E., Campo, P., Tolaymat, T., Suidan, M., Townsend, T.G., 2010. Assessment
1088 of the anaerobic degradation of six active pharmaceutical ingredients. *Sci. Total Environ.*
1089 408(9), 2068-2074.
- 1090 Nakada, N., Tanishima, T., Shinohara, H., Kiri, K., Takada, H., 2006. Pharmaceutical
1091 chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal
1092 during activated sludge treatment. *Water Res.* 40, 3297-3303.
- 1093 Ng, A.N.L., Kim, A.S., 2007. A mini-review of modeling studies on membrane bioreactor
1094 (MBR) treatment for municipal wastewaters. *Desalination* 212(1-3), 261-281.
- 1095 Nguyen, L.N., Hai, F.I., Kang, J., Price, W.E., Nghiem, L.D., 2012. Removal of trace
1096 organic contaminants by a membrane bioreactor-granular activated carbon (MBR-GAC)
1097 system. *Bioresour. Technol.* 113, 169-173.
- 1098 Okabe, S., Oshiki, M., Takahashi, Y., Satoh, H., 2011. N₂O emission from a partial
1099 nitrification anammox process and identification of a key biological process of N₂O
1100 emission from anammox granules. *Water Res.* 45(19), 6461-6470.
- 1101 Omil, F., Suárez, S., Carballa, M., Reif, R., Lema, J.M., 2010. Criteria for conceiving
1102 sewage treatment plants for an enhanced removal of organic micropollutants. Chapter 16
1103 In: *Xenobiotics in the Urban Water Cycle*, pg 283-306. Springer. ISBN: 9 789048 135080.
- 1104 Orlando, E.F., Guillette Jr., L.J., 2007. Sexual dimorphic responses in wildlife exposed to
1105 endocrine disrupting chemicals. *Environ. Res.* 104(1), 163-173.
- 1106 Ortiz de García, S., Pinto Pinto, G., García Encina, P., Irusta Mata, R., 2013. Consumption
1107 and occurrence of pharmaceutical and personal care products in the aquatic environment
1108 in Spain. *Sci. Total Environ.* 444, 451-465.
- 1109 Paredes, L., Fernandez-Fontaina, E., Lema, J.M., Omil, F., Carballa, M., 2016.
1110 Understanding the fate of organic micropollutants in sand and granular activated carbon
1111 biofiltration systems. *Sci. Total Environ.* 551-552, 640-648.
- 1112 Park, J., Yamashita, N., Park, C., Shimono, T., Takeuchi, D.M., Tanaka, H., 2017.
1113 Removal characteristics of pharmaceuticals and personal care products: Comparison
1114 between membrane bioreactor and various biological treatment processes. *Chemosphere*
1115 179, 347-358.
- 1116 Parrott, J.L., Blunt, B.R., 2005. Life-cycle exposure of fathead minnows (*Pimephales*
1117 *promelas*) to an ethinylestradiol concentration below 1 ng/L reduces egg fertilization
1118 success and demasculinizes males. *Environ. Toxicol.* 20(2), 131-141.

- 1119 Phan, H.V., Hai, F.I., Kang, J., Dam, H.K., Zhang, R., Price, W.E., Broeckmann, A.,
1120 Nghiem, L.D., 2014. Simultaneous nitrification/denitrification and trace organic
1121 contaminant (TrOC) removal by an anoxic-aerobic membrane bioreactor (MBR).
1122 *Bioresour. Technol.* 165, 96- 104.
- 1123 Plósz, B.G., Langford, K.H., Thomas, K.V., 2012. An activated sludge modelling
1124 framework for xenobiotic trace chemicals (ASM-X): assessment of diclofenac and
1125 carbamazepine. *Biotechnol. Bioeng.* 109, 2757-2769.
- 1126 Pomiès, M., Choubert, J.M., Wisniewski, C., Coquery, M., 2013. Modelling of
1127 micropollutant removal in biological wastewater treatments: A review. *Sci. Total Environ.*
1128 443, 733-748.
- 1129 Quintana, J.B., Weiss, S., Reemtsma, T., 2005. Pathways and metabolites of microbial
1130 degradation of selected acidic pharmaceutical and their occurrence in municipal
1131 wastewater treated by a membrane bioreactor, *Water Res.* 39, 2654-2664.
- 1132 Radjenović, J., Petrović, M., Barceló, D., 2009. Fate and distribution of pharmaceuticals
1133 in wastewater and sewage sludge of the conventional activated sludge (CAS) and
1134 advanced membrane bioreactor (MBR) treatment. *Water Res.* 43(3), 831-841.
- 1135 Reif, R., Besancon, A., Corre, K.L., Jefferson, B., Lema, J.M., Omil, F., 2011.
1136 Comparison of PPCPs removal on a parallel-operated MBR and AS system and
1137 evaluation of effluent post-treatment on vertical flow reed beds. *Water Sci. Technol.*
1138 63(10), 2411-2417.
- 1139 Reif, R., Suarez, S., Omil, F., Lema, J.M., 2008. Fate of pharmaceuticals and cosmetic
1140 ingredients during the operation of a MBR treating sewage. *Desalination* 221, 511-517.
- 1141 Remy, M., Van der Marel, P., Zwijnenburg, A., Rulkens, W., Temmink, H., 2009. Low
1142 dose powdered activated carbon addition at high sludge retention times to reduce fouling
1143 in membrane bioreactors. *Water Res.* 43, 345-350.
- 1144 Rice, R.G., Robson, C.M., 1982. Biological Activated Carbon-Enhanced Aerobic
1145 Biological Activity in GAC Systems. Ann Arbor SCI, Woburn.
- 1146 Ruiz, G., Jeison, D., Rubilar, O., Ciudad, G., Chamy, R., 2006. Nitrification-
1147 denitrification via nitrite accumulation for nitrogen removal from wastewaters.
1148 *Bioresour. Technol.* 97(2), 330–335.
- 1149 Santos, J.L., Aparicio, I., Callejón, M., Alonso, E., 2009. Occurrence of pharmaceutically
1150 active compounds during 1-year period in wastewaters from four wastewater treatment
1151 plants in Seville (Spain). *J. Hazard. Mater.* 164(2-3), 1509-1516.
- 1152 Serrano, D., Suárez, S., Lema, J.M., Omil, F., 2011. Removal of persistent pharmaceutical
1153 micropollutants from sewage by addition of PAC in a sequential membrane bioreactor.
1154 *Water Res.* 45, 5323–5333.

- 1155 Sigg, L., 2000. Redox potential measurements in natural waters: significance, concepts
1156 and problems. *Redox: Fundamentals, Process and Applications*, Springer,
1157 Berlin/Heidelberg, Germany (2000).
- 1158 Silva-Teira, A., Sánchez, A., Buntner, D., Rodríguez-Hernández, L., Garrido, J.M., 2017.
1159 Removal of dissolved methane and nitrogen from anaerobically treated effluents at low
1160 temperature by MBR post-treatment. *Chem. Eng. J.* 326, 970-979.
- 1161 Silvestre, G., Fernández, B., Bonmatí, A., 2015. Significance of anaerobic digestion as a
1162 source of clean energy in wastewater treatment plants. *Energy Convers. Manage.* 101(1),
1163 255-262.
- 1164 Sipma, J., Osuna, B., Collado, N., Monclús, H., Ferrero, G., Comas, J., Rodríguez-Roda,
1165 I., 2010. Comparison of removal of pharmaceuticals in MBR and activated sludge
1166 systems. *Desalination* 205(2), 653–659.
- 1167 Sirotkin, A.S., Koshkina, L.Y., Ippolitov, K.G., 2001. The BAC-process for treatment of
1168 waste water containing non-ionogenic synthetic surfactants. *Water Res.* 35(13), 3265
1169 3271.
- 1170 Spongberg, A.L., Witter, J.D., 2008. Pharmaceutical compounds in the wastewater
1171 process stream in Northwest Ohio. *Sci. Total Environ.* 397, 148-157.
- 1172 Stephenson, T., S. Judd, B. Jeferson and K. Brindle, 2000. *Membrane Bioreactors for*
1173 *Wastewater Treatment*. 1st Edn., IWA Publishing, London, ISBN: 1 900222 07 8.
- 1174 Stumm, W., Morgan, J.J., 1996. *Aquatic Chemistry: Chemical Equilibria and Rates in*
1175 *Natural Waters*. John Wiley & Sons, New York.
- 1176 Stumpf, M., Ternes, T.A., Wilken, R.-D., Silvana Vianna Rodrigues, Baumann, W., 1999.
1177 Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil.
1178 *Sci. Total Environ.* 225, 135-141.
- 1179 Suárez, S., Reif, R., Lema, J.M., Omil, F., 2012. Mass balance of pharmaceutical and
1180 personal care products in a pilot-scale single-sludge system: influence of T, SRT and
1181 recirculation ratio. *Chemosphere* 89(2), 164-171.
- 1182 Suárez, S., Omil, F., Lema, J.M., 2010. Removal of pharmaceutical and personal care
1183 products (PPCPs) under nitrifying and denitrifying conditions, *Water Res.* 44, 3214-3224.
- 1184 Suárez, S., Carballa, M., Omil, F., Lema, J.M., 2008. How are pharmaceutical and
1185 personal care products (PPCPs) removed from urban wastewaters? *Rev. Environ. Sci.*
1186 *Biotechnol.* 7, 125-138.
- 1187 Tadkaew, N., Hai, F.I., McDonald, J.A., Khan, S.J., Nghiem, L.D., 2011. Removal of trace
1188 organics by MBR treatment: the role of molecular properties. *Water Res* 45(8), 2439-
1189 2451.

- 1190 Tauxe-Wuersch, A., De Alencastro, L.F., Grandjean, D., Tarradellas, J., 2005. Occurrence
1191 of several acidic drugs in sewage treatment plants in Switzerland and risk assessment.
1192 *Water Res.* 39, 1761-1772.
- 1193 Ternes T, Joss A (2006). Human pharmaceuticals, hormones and fragrances. The
1194 challenge of micropollutants in urban water management. IWA Publishing, London.
- 1195 Ternes, T.A., Herrmann, N., Bonerz, M., Knacker, T., Siegrist, H., Joss, A., 2004. A rapid
1196 method to measure the solid-water distribution coefficient (K_d) for pharmaceuticals and
1197 musk fragrances in sewage sludge. *Water Res.* 38(19), 4075-4084.
- 1198 Ternes, T., Bonerz, M., Schmidt, T., 2001. Determination of neutral pharmaceuticals in
1199 wastewater and rivers by liquid chromatography-electrospray tandem mass spectrometry.
1200 *J. Chromatogr. A.* 938(1-2), 175-185.
- 1201 Ternes, T.A., 1998. Occurrence of drugs in German sewage treatment plants and rivers.
1202 *Water Res.* 32 (11), 3245–3260.
- 1203 Terzic, S., Matosic, M., Ahel, M., Mijatovic, I., 2005. Elimination of aromatic surfactants
1204 from municipal wastewaters: Comparison of conventional activated sludge treatment and
1205 membrane biological reactor. *Water Sci. Technol.* 51(6-7), 447-453.
- 1206 Thorpe, K.L., Cummings, R., Hutchinson, T.H., Scholze, M., Brighty, G., Sumpter, J.P.,
1207 Tyler, C.R., 2003. Relative potencies and combination effects of steroidal estrogens in
1208 fish. *Environ. Sci. Technol.* 37(6), 1142-1149.
- 1209 Tran, N.H., Urase, T., Ngo, H.H., Hu, J., Ong, S.L., 2013. Insight into metabolic and
1210 cometabolic activities of autotrophic and heterotrophic microorganisms in the
1211 biodegradation of emerging trace organic contaminants. *Bioresour. Technol.* 146, 721-
1212 731.
- 1213 Tran, H.T., Urase, T., Kusakabe, O., 2009. The characteristics of enriched nitrifier culture
1214 in the degradation of selected pharmaceutically active compounds. *J. Hazard. Mater.*
1215 171(1-3), 1051-1057.
- 1216 Triebkorn, R., Casper, H., Heyd, A., Eikemper, R., Köhler, H.R., Schwaiger, J., 2004.
1217 Toxic effects of the non-steroidal anti-inflammatory drug diclofenac. Part II: cytological
1218 effects in liver, kidney, gills and intestine of rainbow trout (*Oncorhynchus mykiss*). *Aquat.*
1219 *Toxicol.* 68(2), 151-166.
- 1220 van der Aa, N.G., Kommer, G.J., van Montfoort, J.E., Versteegh, J.F., 2011. Demographic
1221 projections of future pharmaceutical consumption in the Netherlands. *Water Sci. Technol.*
1222 63(4), 825-831.
- 1223 Vázquez-Padín, J.R., Morales, N., Gutiérrez, R., Fernández, R., Rogalla, F., Barrio, J.P.,
1224 Campos, J.L., Mosquera-Corral, A., Méndez, R., 2014. Implications of full scale
1225 implementation of an anammox based process as post-treatment of a municipal anaerobic
1226 sludge digester operated with co-digestion. *Water Sci. Technol.* 69(6), 1151-1158.

- 1227 Verlicchi, P., Zambello, E., AlAukidi, M., 2013. Removal of pharmaceuticals by
1228 conventional wastewater treatment plants. In: Petrovic, M., Barcelo, D., Perez, S. (Eds.),
1229 Compr. Anal. Chem. 8. Analysis Removal, Effects and Risks of Pharmaceuticals in the
1230 Water Cycle — Occurrence, and Transformation in the Environment. Elsevier,
1231 Amsterdam, pp. 231–286.
- 1232 Verlicchi, P., Al Aukidy, M., Zambello, E., 2012. Occurrence of pharmaceutical
1233 compounds in urban wastewater: Removal, mass load and environmental risk after a
1234 secondary treatment-A review. *Sci. Total Environ.* 429, 123-155.
- 1235 Verlicchi, P., Galletti, A., Petrovic, M., Barceló, D., 2010. Hospital effluents as a source
1236 of emerging pollutants: An overview of micropollutants and sustainable treatment
1237 options. *J. Hydrol.* 389 (3-4), 416–428.
- 1238 Vieno, N.M., Tuhkanen, T., Kronberg, L., 2005. Seasonal variation in the occurrence of
1239 pharmaceuticals in effluents from a sewage treatment plant and in the recipient water.
1240 *Environ. Sci. Technol.* 39(21), 8220-8226.
- 1241 Widjaja, T., Miyata, T., Nakano, Y., Nishijima, W., Okada, M., 2004. Adsorption capacity
1242 of powdered activated carbon for 3,5-dichlorophenol in activated sludge. *Chemosphere*
1243 57(9), 1219-1224.
- 1244 Wunder, D.B., Bosscher, V.A., Cok, R.C., Hozalski, R.M., 2011. Sorption of antibiotics
1245 to biofilm. *Water Res.* 45(6), 2270-2280.
- 1246 Xue, W., Wu, C., Xiao, K., Huang, X., Zhou, H., Tsuno, H., Tanaka, H., 2010. Elimination
1247 and fate of selected micro-organic pollutants in a full-scale anaerobic/anoxic/aerobic
1248 process combined with membrane bioreactor for municipal wastewater reclamation.
1249 *Water Res.* (44), 5999-6010.
- 1250 Yang, G.F., Zhang, Q.Q., Jin, R.C., 2013. Changes in the nitrogen removal performance
1251 and the properties of granular sludge in an Anammox system under oxytetracycline
1252 (OTC) stress. *Bioresour. Technol.* 129, 65-71.
- 1253 Yi, T. and Harper, W. F., 2007. The Link between nitrification and biotransformation of
1254 17-ethinylestradiol. *Environ. Sci. Technol.* 41(12), 4311-4316.
- 1255 Yi, T.W., Harper, W.F., Holbrook, R.D., Love, N.G., 2006. Role of particle size and
1256 ammonium oxidation in removal of 17 alpha-ethinyl estradiol in bioreactors. *J. Env. Eng.*
1257 132(11), 1527-1529.
- 1258 Zeng, Q.L., Li, Y.M., Gu, G.W., Zhao, J., Zhang, C., Luan, J., 2009. Sorption and
1259 biodegradation of 17 β -estradiol by acclimated aerobic activated sludge and isolation of
1260 the bacterial strain. *Environ. Eng. Sci.* 26(4), 783-790.
- 1261 Zhang, M., Peng, Y., Wang, C., Wang, C., Zhao, W., Zeng, W., 2016. Optimization
1262 denitrifying phosphorus removal at different hydraulic retention times in a novel
1263 anaerobic anoxic oxic-biological contact oxidation process. *Biochem. Eng. J.* 106, 26-36.

1264 Zhang, Z., Gao, P., Su, H., Zhan, P., Ren, N., Feng, Y., 2015. Anaerobic biodegradation
1265 characteristics of estrone, estradiol, and 17 α -ethinylestradiol in activated sludge batch
1266 tests. *Desalination Water Treat.* 53(4), 985-993.